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ABSTRACT OF DISSERTATION 
 
THE EFFECTS OF DIETARY NITRATE AND VITAMIN C ON ENDOTHELIAL FUNCTION 
AND 
OXIDATIVE STRESS BIOMARKERS 
 
Background: Endothelial dysfunction is associated with a decline in the vasodilator nitric oxide 
(NO) and presents alongside other cardiovascular risk factors in the early stages of atherosclerosis. 
Independently, inorganic nitrate and vitamin C supplementation have shown promise in providing 
some restoration of NO bioavailability, reduced oxidative stress, and improvements in endothelial 
function. Some preliminary evidence has suggested that vitamin C may augment the reduction of 
nitrite to further liberate NO and improve cardiovascular health. However, co-supplementation has 
not been adequately studied. Our objective was to compare the effect of inorganic nitrate in the 
form of concentrated beetroot juice (CBJ) with and without vitamin C on changes in clinical and 
blood biomarkers of endothelial dysfunction. 
Methods: Older adults between 50-70 years with low density lipoprotein (LDL) >130 mg/dL and 
RHI score less than 2 were enrolled in a crossover randomized -double blinded study. Two 4-week 
intervention periods were separated by a 2-week washout period. Subjects were assigned randomly 
to start with either CBJ with 1000 mg of vitamin C (NC) or CBJ with a matched vitamin C placebo 
(N), then switched to the alternate treatment. Vascular testing was measured by EndoPAT to assess 
reactive hyperemia index (RHI) before and after each interventional period. Fasting blood samples 
were also collected for serum lipid parameters, plasma vitamin C, plasma oxidized LDL, and 
plasma NO metabolites to compare the differences between treatments. 
Results: Of the 23 enrolled subjects, 18 completed all study visits (7 male, 11 females; age 53-70 
years). No significant differences were observed in RHI change (p>0.05) between the two 
treatments. Some subjects showed a greater improvement in RHI after nitrate and vitamin C who 
entered the study with a lower baseline RHI score than those with mean baseline RHI score >1.67 
 
 
(RHI: 1.23 vs 1.75; p=0.02). Changes in plasma nitrate and nitrite were significantly different 
between treatments (p<0.01 and p=0.03 for nitrate and nitrite, respectively). NC produced a greater 
reduction in the ratio of oxLDL/NOx (p=0.02). There were significant differences between 
treatment groups for LDL cholesterol (p= 0.049), total cholesterol (p=0.05), and triglycerides 
(p=0.03) with lower concentrations observed following the NC intervention. HDL was not 
influenced by dietary nitrate supplementation individually nor in combination with vitamin C. 
Conclusions : Co-supplementation of CBJ and vitamin C was effective at enriching the NO pool 
and reducing a marker of oxidative stress suggesting a potential to improve endothelial function, 
and reduce the progression of atherosclerotic disease. 
 
Keywords: Dietary nitrate, Vitamin C, Endothelial Function, Nitric Oxide, Oxidized Low-density-
Lipoprotein, Lipid Profile.  
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 1 
 INTRODUCTION 
  Background  
Cardiovascular diseases (CVDs) have contributed to a rampant proportion of mortality in 
the United States [1, 2] resulting in more than 859,000 deaths per year. CVD causes a huge 
economic burden to US health care system costing $199 billion a year and causing $131 billion in 
lost productivity from premature death. Coronary heart disease (CHD) is the most common cause 
of death attributable to CVD in the United States, killing over 366,800 people annually. In the U.S, 
the estimated annual incidence of heart attack is 720,000 with an average age of 65.5 years for 
males and 72 years for females [3]. Hypercholesterolemia is one of the main cardiovascular risk 
factors that contribute to increased risk of atherosclerosis (AS), coronary mortality, and morbidity 
[3, 4] (see Table 1-1). In 1963, Keys and coworkers conducted a study of 12763 men aged 40-59 
years from 7 countries and found that high cholesterol levels were associated with the prevalence 
of CHD [5-9].  A report from the American Heart Association (AHA) estimated that approximately 
100 million U.S. adults have total cholesterol levels of 200mg/dL or greater. Of this number, 31 
million have levels greater than 240mg/dL [10]. Research has clearly suggested that the elevation 
of plasma oxidative stress and high total cholesterol concentrations in hypercholesterolemia 
potentiate impairment in the endothelial function that represents early as a key first step toward AS 
development [11, 12]. Impairment of endothelial function is an important mechanism for 
cardiovascular (CV) risk [13]. Early studies demonstrated a positive relationship between 
endothelial dysfunction (ED) and cardiovascular risk factors [14-17]. Endothelial dysfunction (ED) 
is commonly observed in a number of chronic diseases such as diabetes mellitus, metabolic 
syndrome, hypertension, and dyslipidemia [18]. Numerous studies have documented that 
improving the functional integrity of the endothelium is inversely associated with CV risk events, 
including AS [19, 20]. Thus, as impaired endothelial function is a reversible and important 
surrogate for AS, early recognition and intervention may have therapeutic and prognostic value in 
vulnerable populations to slow the onset or progression of AS, and reduce the incidence of 
cardiovascular risk events [21]. Therefore, it is imperative to identify novel approaches to restore 
endothelial function and reduce the risk of major CVD events. Some studies have looked at using 
nutritional interventions to improve/restore endothelial function. Compelling evidence of 
modulating vascular function with dietary interventions are emerging and deserve greater attention 
as a viable option on modulating key markers of cardiovascular health [22]. For instance, the 
cardio-protective effects of green leafy vegetables are attributed to the high nitrate content and the 
presence of other active components including vitamin C, polyphenols, potassium, or carotenoids 
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[23]. Diet-derived inorganic nitrate may have impact on CVD prevention through the enhancement 
of vascular health by increasing blood flow, dilating arteries, and inhibiting platelet aggregation 
and leukocyte adhesion [22-24]. Questions have been raised whether the addition of vitamin C 
supplement complement the biological benefits of dietary nitrate by improving vasodilation 
through facilitating the conversion of salivary-derived nitrite to nitric oxide (NO), and diminishing 
oxidative damage [25, 26]. Therefore, the primary goal of this dissertation is to evaluate the additive 
effect of dietary nitrate combined with vitamin C on endothelial function and oxidative stress 
markers in patients at risk of CVD. 
Table 1-1-1. Modifiable and non-modifiable risk factors for atherosclerotic CVD 
Modifiable Risk factors Non-Modifiable Risk factors 
Diabetes mellitus Age 
Hypertension Gender 
Dyslipidemia Family history 
Obesity Genetics 
Tobacco smoking Ethnicity 
Poor diet  
Physical inactivity  
 Atherosclerosis 
Atherosclerosis is defined as a complex inflammatory disease that occurs primarily in the 
arterial intima at susceptible arterial sites in the coronary arteries [27]. Atherosclerosis develops 
progressively through accumulation of cholesterol- rich lipids, mainly low-density lipoprotein 
cholesterol (LDL) and an inflammatory response. These changes occur along a life-long continuum 
that begins with the development of early fatty streak during childhood or adolescence in response 
to endothelial injury, followed by fibrous plaque in late adolescence and early adulthood (15-30 
years), advancing to an atheroma that occurs in older adults aged ≥55 years resulting in increased 
chances of a life-threatening thrombosis [28]. Therefore, the clinical manifestation of AS is silent 
in most people until later in life. The three most important factors in atherosclerotic lesion are 
endothelial dysfunction, alterations in lipid metabolism, and inflammation [28].  
 Pathophysiology of atherosclerosis  
The first key stage in atherogenesis as proposed in "Response to Injury Theory” is 
dysfunctional alterations in the endothelium. Endothelial dysfunction induced by number of 
irritants including physical injury or stress as a result of direct trauma, turbulent blood flow, or 
circulation of toxins (reactive oxygen species (ROS)) from the presence of one or more 
cardiovascular risk factors for example; tobacco smoking, hyperlipidemia, hyperglycemia, 
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hypertension, or obesity [11, 29]. The second stage is fatty streak development in the context of 
local ED within the intima (sub-endothelium) where the underlined proteoglycan becomes exposed 
and permits an increase of LDL infiltration, deposition, and retention within the sub endothelial 
layer. This ultimately results in increased susceptibility of endothelial surface lipids to oxidative 
modification in the arterial wall that plays an important role in the activation of endothelial cells 
[27]. Consequently, recruitment of leukocytes and adhesion of monocytes to the activated 
endothelial layer occur [30]. Monocytes differentiate into macrophages that uptake oxidized low- 
density lipoprotein (oxLDL) by their scavenging receptors such as (LOX-1) to form foam cells. 
These foam cells which undergo inflammatory processes, secrete proinflammatory substances such 
as interleukin 1 (IL-1), and tumor necrosis factors (TNF) and growth factors [27, 31]. Subsequently, 
vascular smooth muscle cell proliferate and migrate to the endothelium. Thereby promoting plaque 
formation by synthesis of extracellular matrix such as collagen, elastin, and proteoglycan to form 
the fibrous cap [32] [31]. The final step is plaque rupture or thrombosis in which all the 
thrombogenic plaque materials get exposed and leads to blood clot formation producing blockage 
of arterial blood flow (myocardial infarction) [30].  
In clinical settings, the estimation of risk for atherosclerotic CVD (ASCVD) depends on 
identifying and quantifying risk factors. However, this clinical tool may be not enough to assess 
individual’s risk [33]. Evidence in literature suggest that an impairment of endothelial function acts 
as an independent predictor for CV events [34-36], and the pathologic changes of  
hypercholesterolemia in CV system are initiated when endothelial erosions appear [33].  
 Endothelium 
Endothelium is a monolayer of cells that lines the inner layer of blood vessels forming an 
interface between the vascular wall and blood lumen [37]. The healthy endothelium maintains 
vascular homeostasis through optimal response to physical and chemical signals such as blood 
pressure (BP), shear stress, and hormonal stimuli. It produces of a wide range of vasoactive 
substances participating in modulation of coagulation, inflammatory reactions, as well as regulation 
of vascular tone that relax or constrict blood vessels [37]. Some of the vasodilatory substances 
released by endothelium include NO, prostacyclin I2 (PGI2), different endothelium-derived 
hyperpolarizing factors and protein C/protein S [19, 29, 37, 38]. Therefore, maintaining the 
integrity of endothelial function is important for overall vascular health [39, 40].  
Under pathological conditions, such as the presence of CVRFs (hypercholesterolemia), the 
endothelium releases various vasoconstrictive, pro-inflammatory, pro-coagulant substances 
include endothelin-1, Ang II, thromboxane A2, platelet activating factor, and ROS. The production 
of the aforementioned substances shifts the balance toward over production of pro-oxidant, pro-
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inflammatory, and pro-thrombotic effects that assist with platelet aggregation [38, 41, 42]. This 
imbalance between vasodilators and vasoconstrictors is an essential factor for the impairment of 
endothelial function that is further aggravated by oxidative stress [12]. Overall, an impairment of 
endothelial function is the early key event in the pathogenesis of AS which can independently 
predict CV events [43, 44]. Several mechanisms have been identified underlying ED in arteries 
predisposed to AS. These mechanisms can be summarized into two types, which either impairs NO 
production or increases NO inactivation/degradation as a result of oxidative stress [37, 45].   
 Importantly, pathophysiologic changes in endothelium can be detected before structural 
changes in the vascular wall, and can be partially repaired [37, 46]. Multiple studies have 
documented that improving the functional integrity of the endothelium is inversely associated with 
CV risk events, including AS [19, 20]. Thus, as endothelial function is reversible at every stage of 
AS and acts as an important surrogate for AS [33], early recognition and intervention may have 
therapeutic and prognostic values in vulnerable populations to slow the onset or progression of AS, 
and reduce the incidence of CV risk events [21]. These data suggest targeting endothelial function 
and correcting the true cause of malfunction (reduction of NO) by identifying appropriate 
interventions in patients at risk of CVD is a great of concern.   
 Factors known to modulate endothelial function 
 Nitric oxide 
In 1980, Furchgott and Zawadzki first discovered the significance of NO as a predominant 
endothelium-derived relaxing-factor for CV health [47]. NO is recognized as a master signaling 
gaseous molecule that is involved in many physiological process of human organ systems including 
circulatory system[48]. The traditional pathway to synthesize NO in endothelium is from the amino 
acid L- arginine by the enzyme called endogenous nitric oxide synthase (eNOS) [47]. The activity 
of this enzyme depends on the presence of oxygen molecules as well as tetrahydrobiopterin (BH4), 
flavin adenine dinucleotide (FAD), and flavin mononucleotide (FMN), the intracellular 
concentration of calcium ions, and the co-substrate nicotinamide-adenine dinucleotide phosphate 
hydrogen (NADPH) [18]. 
In response to vascular stimuli such as shear stress, bradykinin, acetylcholine, or histamine, 
NO synthesis and release are triggered by increasing the intracellular concentration of calcium that 
further binds with calmodulin to form calcium calmodulin complex. This complex detaches eNOS 
from its binding with Caveolin to facilitate the activation of eNOS in order to catalyze NO synthesis 
[49]. Eventually, this gaseous molecule vasodilates locally by diffusing into vascular smooth 
muscle cells to activate soluble guanylate cyclase (sGC) that catalyzes the conversion of guanosine 
triphosphate (GTP) to cyclic guanosine monophosphate (GMP), and thereby causes vascular 
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smooth muscle relaxation [37, 50] . Vasodilation effect results in improved blood flow, and delivery 
of oxygen and nutrients to a variety organs and tissues [22]. Aside from vasodilatory potential, NO 
has anti-thrombotic and anti-proliferative roles which have been supported by studies of animal 
models of AS [49, 51]. Moreover, studies have been shown that NO has antioxidant properties, 
limits lipid peroxidation and mitochondrial ROS generation [52]. These data suggest that due to 
the strong vascular effects induced by NO, interest in maintaining circulatory NO pool remains a 
priority for future research. 
A decrease of NO bioavailability has been suggested as a cause for endothelial 
phenotypical changes [49], and has been considered as a hallmark of ED associated AS [18]. 
Evidence has demonstrated that lacking of eNOS induces hyperlipidemia, hypertension, and insulin 
resistance [51]. Several mechanisms have been identified underlying ED in arteries predisposed to 
AS. These mechanisms can be summarized into two types, which either impairs NO production or 
increases NO inactivation/degradation as a result of oxidative stress [37, 45]. There are several 
factors that can modulate NO synthesis and degradation including the eNOS mRNA and protein 
expression and the amounts of eNOS inhibitor called asymmetric dimethylarginine (ADMA) [51], 
eNOS uncoupling , and overproduction of ROS, mainly superoxide radicals [45]. The eNOS 
uncoupling resulted from either the depletion of the substrate (L-arginine) or the oxidative 
modification of the cofactor (BH4) resulting in superoxide anion production rather than NO 
formation [34].  
 Oxidative stress  
Oxidative stress has a causal role in altering vascular function and tone [34, 49]. Oxidative 
stress defined as a state in which excess production of ROS (free radicals) disturb its balance with 
antioxidants defenses [53]. Free radicals, are highly reactive, consist of oxygen-containing 
molecules with an odd number of electrons, which allow them to react easily with other molecules 
and consequently cause tissue and cell damage [54].  
One of the major sources of ROS production in atherosclerosis is NADPH oxidase (NOX). 
These oxidative enzymes use NADPH as an electron donor to generate endothelial oxidative 
superoxide leading to degradation of either NO or it cofactor BH4 before leaving the endothelium 
[49]. Other sources of ROS have been identified within vascular tissues are xanthine oxidase, 
uncoupled eNOS, mitochondrial respiratory chain, and lipoxygenase. ROS include 1) free radical 
such as superoxide anion (O2–), hydroxyl radical (OH), and 2) non-free radicals such as; hydrogen 
peroxide (H2O2), hypochlorous acid (HOCl), and peroxynitrite (ONOO–) [45, 54]. To estimate the 
degree of oxidative stress, levels of circulating oxidative stress biomarkers can be detected by 
 
 
6 
measuring stable products produced by ROS such as serum lipid hydroperoxides, plasma 
malonaldialdehyde, plasma or urinary output of F2-isoprostanes, or plasma oxLDL [47, 50, 55]. 
The antioxidant scavengers in human subjects and animal models with AS are classified 
into enzymatic and non-enzymatic sources. The enzymatic sources  are superoxide dismutase 
(SOD), glutathione peroxidase (GPx), and catalase, while the non-enzymatic sources such as 
vitamins C, vitamin E and beta-carotene, which present with very high levels in plant based sources 
including fruits, vegetables, and whole grains [56]. SOD converts superoxide to hydrogen peroxide 
(H2O2), which then can be detoxified to water (H2O) and oxygen via either GPx or catalase [45, 
57]. The capabilities of antioxidants defenses are attenuated with the excess production of ROS 
[58]. The findings from antioxidant vitamins interventions for cardiovascular health are 
controversial and more detail will be discussed in vitamin C section, pages 22&23. 
 Health status 
 As mentioned previously, the integrity of vascular health is affected by the presence of 
traditional risk factors of CVD such as aging, hypercholesterolemia, smoking, and diabetes. This 
dissertation primarily discusses the effect of aging and hypercholesterolemia on endothelial 
function. Aging is an independent risk factor of ED [18]. Vascular health of older individuals is a 
relevant clinical concern due to a structural and functional changes in the vascular system 
associated with aging. It is associated with functional abnormality of NOS expression/activity and 
cGMP-mediated vascular relaxation for multiple mechanisms [51, 59]. Furthermore, 
overproduction of oxidative stress and oxidized LDL are the main causative factors in aging leading 
to a decline in NO synthesis and bioavailability, further induces abnormality in endothelial function 
[60]. In healthy men greater than 40, the endothelial dependent vasodilation has been shown to 
decrease by 0.21% annually [61]. Other reports supporting that endothelium-dependent 
vasodilation declines significantly with age, have demonstrated a loss of greater than 50% of NO 
in adults after the age of 60 [62, 63]. Therefore, these phenomena highlight the importance for 
evaluating interventions targeting the NO pathway or providing an alternative source of NO to slow 
the progression of NO insufficiency in older individuals at risk of CVD [64, 65]. 
a. Hypercholesterolemia 
 The association between impaired endothelium dependent vasodilation and elevated LDL 
levels are well documented [37]. Early studies in animal models of hypercholesterolemia have 
examined the link between hypercholesterolemia and a reduction in endothelium dependent 
vasodilation in large arteries [66-68]. These findings were confirmed by human clinical studies that 
assessed endothelial function in healthy and hypercholesterolemic subjects and demonstrated an 
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impairment of NO release with hypercholesterolemia subjects compared to normocholesterolemic 
controls [69, 70].  
 Numerous observations supporting the view that high cholesterol levels in the blood 
stream, particularly LDL (often referred to as bad cholesterol) induces an increase of vascular 
oxidant load of ROS, particularly superoxide anion free radicals in the vascular wall therefore 
resulting in changes of endothelial permeability and induce an increase in LDL retention into the 
arterial wall [71-74]. In fact, Ang II concentration is increased during hypercholesterolemia and 
other atherosclerotic diseases, which in turn stimulate ROS derived from NOX and xanthine 
oxidase activation within endothelial cells and smooth muscle cells [75]. Over production of 
superoxide anions consume NO to produce potent form of reactive nitrogen species (RNS) called 
peroxynitrite (OONO-), consequently, generates oxidized LDL. Increased (OONO- ) may in turn 
uncouple eNOS, inactivate NO, and inhibit sCG activity [76]. This reaction is faster than the 
reaction between superoxide radical and SOD, which may explain the failure of SOD 
administration to improve vascular health in hypercholesterolemia [77]. Since loss of NO 
generation and oxidative stress in AS are ultimately related to vascular health, identifying effective 
pharmacological or lifestyle interventions that augment the cumulative NO pool and induce a 
further reduction in oxidative stress biomarkers may provide a novel strategy to prevent and treat 
ED associated cardiovascular risk factors.  
 There are extensive studies in literature documenting that ED as measured by FMD is 
reversible by modifying risk factors [78-80]. Researchers have investigated whether improvement 
of endothelial NO-dependent vasodilation was correlated with cholesterol lowering. Data have 
suggested that lowering cholesterol even if the levels are within the normal range could have a 
beneficial impact on improving endothelial function and NO production and release [42]. 
Experimental studies have shown that ED in a primate model of AS are reversible after removal of 
the LDL [37, 81]. In addition, when cholesterol lowering treatments are removed, it has been 
observed that ED returns quickly [37].  
Some investigators confirmed that cholesterol level reductions resulting from dietary 
modification improved endothelium dependent vasodilation. For example, Fuentes et al, (2001) 
observed a recovery of ED in hypercholesterolemic men after lowering cholesterol levels with diet 
high in fruits and vegetables for 28 days [82]. As ED is treatable/reversible with lifestyle 
modifications, much attention of cardiovascular research has focused on the nutrition arena because 
dietary intervention seems to be feasible and low-cost way to manage patients at risk of CVD [22]. 
Therefore, this thesis focused on investigating a novel dietary supplement combination that may 
have a beneficial effect in cholesterol profile and endothelial function in hypercholesterolemia. To 
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date, there is limited knowledge about the effects of inorganic nitrate in hypercholesterolemia. 
Whether or not dietary nitrate supplementation has a beneficial effect on cholesterol profile is 
eagerly awaited [74, 83].  
 OxLDL and atherosclerosis 
 LDL oxidation is an important determinant involved in early and advancement stages of 
atherosclerotic plaques development [27, 30]. The oxidative modification hypothesis of 
atherosclerosis has emphasized the importance of oxidative modification step in atherogenesis [84]. 
This hypothesis proposes that small dense LDL is easily penetrate to sub-endothelial space and is 
more prone to oxidative modification by ROS prior to being engulfed by macrophages at sites of 
vascular cell activation [27]. The LDL oxidation is a complex process in which the protein and 
lipid components of LDL particles are susceptible to oxidative reactions during LDL oxidation [85, 
86].  LDL is converted to minimally modified LDL (mmLDL) after infiltration in the artery [30]. 
This mmLDL induces the expression of intracellular adhesion molecules (ICAM) and vascular cell 
adhesion molecules (VCAM) to trigger the adhesion and recruitment of monocytes in the 
endothelial cells, and then undergoes oxidation to form fully or extensively oxLDL [58]. The exact 
mechanism of how and when oxLDL is formed and released to circulatory blood are still unclear 
[87]. However, there are different mechanisms contributing to the generation of oxLDL besides 
peroxynitrite including myeloperoxidase, lipoxygenase, phosophlipase A2,  metal ion-mediated 
oxidation (iron, copper), superoxide generators (xanthine oxidase, NADPH-oxidase), thiol-
dependent oxidation, and other radical generation compounds [46, 85]  followed by increased 
oxLDL recognition by the macrophages.  
 Some of the properties of oxidized LDL include the following: The new epitops of oxLDL 
inhibit LDL recognition by LDL receptors on macrophages [86]. OxLDL is a ligand for acetyl LDL 
receptor expressed in macrophages and termed as scavenger receptor and Lox-1[88]. These 
receptors are not down regulated as the native LDL receptors, and have high affinity to oxLDL 
leading to accumulation of intracellular cholesterol in the macrophages that turned to a foam cell 
formation. LDL oxidative modification plays a pivotal role in the development of cell apoptosis 
[27, 85].  
 Human studies clearly support that the concentration of oxidized LDL matters more than 
native LDL concentration since the former is the atherogenic form that enhance the impairment of 
the endothelial vasodilator response in endothelial cells more than does the native LDL levels both 
in large vessels and in the microcirculation [89]. Increased atherogenic lipids (oxLDL) promotes 
activation and dysfunction in endothelial cells in a dose dependent way that contribute mainly with 
the growth of atherosclerotic plaques and then CAD [27, 32, 37].  
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 Plasma oxLDL 
 It has been long believed that oxLDL not merely accumulates in local inflammatory tissues, 
but can be transferred between vessel wall and the circulation [88]. Increased levels of circulating 
oxLDL have shown a positive correlation with severity of cardiovascular risk factors  in some 
studies, specifically with age-related chronic metabolic diseases [46, 60]. A positive linear 
relationship has been established between plasma oxLDL and dyslipidemia in middle aged and 
elderly subjects [46]. Higher levels of oxLDL are positively correlated with LDL and apoB-100 
concentrations [90]. Matsumoto et al. (2004) have suggested that circulating oxLDL could be used 
as an additional tool for coronary endothelial function. [91].  Matsumoto et al. observed a 
correlation between plasma oxLDL and endothelial function in coronary macro and micro vascular 
responses compared to conventional lipid parameters. Further studies are needed to clarify the 
mechanisms underlying the existence of oxLDL levels in the blood [92, 93]. The existence of 
oxLDL in the circulation is strongly confirmed by the presence of autoantibodies against oxLDL 
in atherosclerotic patients [91]. Evidence highlighted the importance of antibody selection to detect 
different epitopes of oxidized apoB or oxidized lipids [90].  To date, three monoclonal antibodies 
have been used in human circulating plasma to determine the relative changes in oxLDL levels 
using an enzyme –linked immunosorbent assay (ELISA) [92]. 1) oxLDL-DLH3 antibody and 2) 
oxLDL-E06 antibody recognize phosphatidylcholine moiety of oxidized phosphatidylcholine (ox-
PC). 3) oxLDL-4E6 antibody is the most widely used antibody to detect the MDA lysine epitope 
of apoB 100 moiety of oxLDL [88, 90].  
 Evidence has shown that diet and lifestyle modification strategies play roles in 
atherogenesis as they can reduce LDL oxidation levels. For example, Barona et al. (2012) in a cross 
over clinical trial demonstrated that the consumption of polyphenol derived from grape juice 
reduces the oxLDL in a form of reducing I-CAM molecules after 4 weeks treatment compared to 
placebo [94]. As another example, Velmurugan et al. (2015) found a trend for a greater reduction 
of oxLDL levels after administering 250 ml of beetroot juice (~6 mmol of dietary nitrate) for 6 
weeks in untreated hypercholesterolemia [74]. Of relevance to this dissertation, it is not well 
understood whether the specific dose or duration of dietary nitrate supplementation attenuates 
oxidative stress biomarkers in hypercholesterolemia subjects. Further studies are needed to draw a 
conclusion if dietary nitrate may regulate and/ or reduce plasma oxLDL concentrations itself [74].  
 Assessment of endothelial function 
 Loss of NO bioavailability is an index of ED that is associated with most, if not all, cv risk 
factors [78]. In clinical settings, there is neither a standard blood chemistry test nor prescribed 
therapy to diagnose and restore NO status effectively [18]. However, ED can be detected using 
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vascular testing that help with understanding vascular health prior to the development of AS lesion 
[95] . 
 There are different techniques have been developed to assess the pathophysiological 
function of endothelium in humans: 1) invasive technique via infusion of endothelial dependent 
vasodilator such as acetylcholine (ACH), serotonin, and bradykinin. 2) non-invasive technique via 
reactive hyperemia acts as a trigger to induce the release of endothelial dependent vasodilator 
NO[33]. The invasive techniques were not feasible for general population because they are 
expensive, time invasive, and only suited for patients requiring angiogram [13]. Therefore, non-
invasive techniques have been introduced to assess macrovascular and microvascular endothelial 
function in peripheral arteries in response to reactive hyperemia [13]. 
 Non-invasive assessment  
 The most common non-invasive method is flow mediated dilation (FMD), ultrasound 
based method [96], which reflects conduit artery vasodilation. Assessment of vascular function 
with FMD is the gold standard technique [96]. It measures the diameter changes in diameter of 
brachial artery (macro vascular beds) at rest and post reactive hyperemia [33]. The most common 
advantage of this method is that it measures the diameter changes of the brachial arteries response 
and is mainly dependent on endothelial NO release. FMD has been widely studied in clinical 
research, and has been correlated significantly with coronary artery endothelial dysfunction, and 
Framingham risk score [78]. Also, studies have demonstrated that impaired FMD has been 
associated with the presence of traditional cardiovascular risk factors [78]. However, this technique 
requires expensive equipment, is highly operator dependent, and needs an expert sonographer [97]. 
These methodological challenges may limit its application in research field and clinical practice 
[78].   
 Therefore, another simpler non- invasive technique has been developed and received 
greater attention recently [13]. The protocol of this technique is based on the same physiological 
mechanism as FMD called reactive hyperemia peripheral artery tonometry (RH-PAT) [97]. The 
assessment of endothelial function with PAT measurement began in early 2000 to measure vascular 
changes in subjects with obstructive sleep apnea, and then applied to vascular testing for 
cardiovascular research [95, 98]. RH-PAT is intended for detection of ED as measured by using 
the EndoPAT 2000 device (Itamar Medical Ltd, Caesarea, Israel) [99]. The main advantages of this 
system has encouraged researchers to use this technique in clinical trials  are that it is operator 
independent, less expensive, automated analysis, and easily performed[99]. With this method, 
finger plethysmography records digital pulse wave amplitude (PWA) changes in the arterioles 
(microvascular beds) of the finger at rest and after reactive hyperemia to calculate the reactive 
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hyperemia index (RHI) [95, 97]. This RH-PAT method was chosen in this dissertation work and 
additional details describing endoPAT technique is provided in chapter 2. 
 Clinical significance of RH-PAT measurements 
 Similar to FMD, validation studies have demonstrated that impairment in peripheral finger 
endothelial function, which is translated into a reduction of RH-PAT ratio, was associated with 
cardiovascular risk factors including diabetes, smoking, overweight, low HDL, and high 
lipoprotein cholesterol [97, 100].  More importantly, PAT like FMD can predict independently the 
expression of cardiovascular disease events and detect the effect of disease on endothelial function 
[95] as shown in aged subjects with low risk of CVD [101] and  healthy older adults [102].  
 Data describing the correlation between PAT and FMD is contradictory [97]. In spite of 
conflicting results that exist in the literature describing the correlation between these two 
measurements, the largest two cohort studies, Framingham heart study and Gutenberg heart study, 
have demonstrated a modest correlation between PAT and FMD [78, 103]. Both studies assessed 
the relation of brachial and digital measures of endothelial function with traditional cardiovascular 
risk factors. Each study recruited about 5000 subjects and demonstrated that PAT ratio as well as 
FMD was reduced when increasing the following factors: body mass index (BMI), fasting glucose, 
and lipid profile [95]. However, different responses of PAT and FMD have been observed. 
Furthermore, an attenuated PAT ratio was not associated with hypertension and inflammation 
whereas a reduced FMD was inversely associated with systolic blood pressure [103]. Moreover, 
while a reduced FMD was associated with increasing age as shown in the Framingham heart study 
[104, 105], the RH-PAT ratio was found to be positively associated with age [95]. This lack of 
correlation might be explained, in part, by the use of different measurement sites of the cuff position 
(Forearm rather versus upper arm). FMD performed with upper arm occlusion noted a better 
correlation than forearm compared with that of shown in previous studies. Another explanation 
could be that the different physiological mechanisms underlying the response of reactive hyperemia 
between these techniques  [97]. The use of either FMD or RH-PAT comes with both strengths and 
weakness. Most of the clinical studies described that the FMD approach in conduit arteries is 
principally mediated by endothelium-derived nitric oxide in response to reactive hyperemia [106]. 
According to microvascular reactive hyperemia (PAT) and NO bioavailability, few studies 
investigated the important role of NO in regulation of digital RH in humans [98, 107-109]. 
However, number of studies reported that PAT responses is partly dependent on nitric oxide, and 
there is a possibility that other mechanisms could affect PAT results than strict NO dependent 
vasodilation [78, 97, 110, 111]. Thus, digital PAT is a promising approach in evaluating endothelial 
function but it may not be interchangeable to FMD [98, 101]. Therefore, additional studies are 
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required to evaluate the relationship of the PAT response to NO following therapeutic interventions 
that target NO pathway [98]. 
 Reproducibility is one of the main concerns investigators should take into account when 
compared specific testing technique is employed [78]. Although data describing the test-retest 
reliability of PAT examinations are scarce [99, 112], published studies have reported a good 
reliability of PAT in healthy and metabolic syndrome samples. Two PAT measures across intervals 
greater than 1 week (mean interval of 19.5 ± 6.2 days), powered at 0.90 were highly repeatable of 
a relatively small sample size (15-30) [99]. Likewise, five repetitive PAT measures conducted 1 
week a part for 20 patients with metabolic syndrome showed robust repeatability with intra-class 
correlation of 0.74 [101]. In addition, the between- day variability was similar (11%) between PAT 
and FMD measurements when performed within an interval of 2 days under same circumstances 
in a small study included 18 male patients with CAD [113].Thus, we can conclude that RHI has a 
good reliability for separate day measurements [113].  
 PAT response to dietary interventions 
 Current evidence in cardiovascular research and prevention of CVD is not sufficient to 
evaluate the utility of PAT measure to assess therapeutic interventions in clinical settings [78, 95]. 
Only few studies were published about the reversibility of PAT following therapeutic interventions 
[98] and yielded mixed results [107, 114-116]. In a RH-PAT study conducted by Kim and 
colleagues (2011), the effects of lycopene on markers of oxidative stress and endothelial function 
were examined [114]. In this study, 126 healthy men with impaired endothelial function, who 
frequently smoked cigarettes or consumed alcohol, were placed into three groups: 39 placebo, 41 
on 6mg of lycopene supplement, and 41 on 15 mg of lycopene supplement. The intervention period 
was 8 weeks. Results revealed that RH-PAT index was increased from baseline by 23% (1.45 ± 
0.09 vs 1.79 ± 0.12; p <0.05) compared to the other groups after treatment, suggesting that RHI 
significantly responded to the dietary intervention [114]. Another study done by Kwak et al. (2012) 
looked at the effect of rice containing resistant starch on markers of endothelial function and 
oxidative stress using RH-PAT [116] . This study included 90 patients with prediabetes or newly 
diagnosed with type 2 diabetes. Patients were randomly assigned to two groups: either a group 
consuming rice containing 6.51 g resistant starch or a control rice group. The intervention period 
was 4 weeks. Results showed significant increases in serum NO levels and RH-PAT index from 
baseline in the interventional group compared to control group. The authors found positive 
correlation between serum total NO, RH-PAT, and superoxide dismutase (SOD) activity. Similarly, 
Nogueria et al, (2012) showed a significant improvement on RH-PAT post 4 weeks of 50 g high- 
polyphenol dark chocolate supplement in overweight and obese stage 1 hypertensive subjects with 
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no significant changes in lipid profile [115]. Changes in RH-PAT index over the 4-week of dietary 
treatment suggesting a good relationship between PAT response, and dietary intervention. Further 
research is needed to examine if PAT signals can be a surrogate endpoint for monitoring additional 
dietary supplement interventions targeting NO such as dietary nitrate or vitamin C, particulary if 
NO is the primary objective for investigation [98].  
 Beneficial dietary approaches for CVD  
Over the past few decades, a number of studies have emerged describing the association between 
dietary patterns and metabolic cardiovascular risk factors. The main beneficiary dietary approaches 
for CVD is a diet rich in fruits and vegetables [117]. Mediterranean and vegetarian diets are 
associated with lower blood pressure and further reduced incidence of CVD in different populations 
[83, 118, 119]. Other studies have tested Dietary Approaches to Stop Hypertension (DASH) diet 
and supported the thesis that diet rich in fruits and vegetables lower blood pressure [120].  
 While the consumption of fruits and vegetables are well- known for the beneficial effect 
on cardiovascular health, the key dietary constituent for this effect is not established yet [83]. 
Possible contributors include antioxidant vitamins like vitamin C and E [121], potassium [122], 
fiber, bioactive phytochemicals such as polyphenol [117], and other bioactive components that are 
not classified as nutrients but have protective cardiovascular effects known as dietary nitrate [123]. 
Much research interest was focused on the effect of antioxidant vitamins, however large scale 
clinical trials failed to suggest that isolated supplements of antioxidant vitamins are the key 
mediators for cardiovascular benefits [83]. Additional large cohort studies conducted by Willet and 
colleagues have suggested that diet rich in green leafy vegetables have more potentially bioactive 
compounds than a single isolated dietary supplement constituent and thus provide a greatest 
protection against cardiovascular mortality and morbidity [83]. Therefore, researchers have 
analyzed different types of food to figure out the exact mechanism underlying the green leafy 
vegetables effect on cardiovascular health [124].  They have demonstrated that the highest 
component of green leafy vegetables is dietary nitrate with estimates indicating up to 20mmol of 
dietary nitrate per day [124]. Scientific research has grown exponentially in recent years due to 
compelling evidence of human studies showing that high levels of nitrate and nitrite of the 
vegetables provide favorable cardiovascular effects and could confer the lowering BP effect of 
green leafy vegetables on CV system [124-126]. These include enhancement of NO bioavailability 
in vasculature and vasodilation [124]. Theoretically, studies suggested that dietary nitrate is 
biologically active when it is bio-activated with agents such as vitamin C to release the vasodilator 
NO [127]. Despite of all these health benefits, research about nitrate supplementation in humans is 
relatively new [22]. In the following sections, the potential therapeutic roles of both dietary nitrate 
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and vitamin C in cardiovascular risk markers including NO signaling in endothelium, oxidative 
stress, and lipids will be discussed with more detail.  
 Dietary nitrate and nitrite 
 Dietary nitrate is mainly obtained from plant-based sources [123, 124]. Eighty-five percent 
of dietary nitrate is derived from green leafy vegetables such as arugula, spinach, lettuce, and kale 
as well as beetroot, and the remainder from drinking water (the amount permitted in the US is 44 
mg nitrate/liter) [128]. There are environmental factors that may affect the concentration of nitrate 
content of vegetables from batch to batch such as temperature, fertilizer use, and sunlight exposure 
[126]. Beetroot juice is a rich natural source of dietary nitrate and the most common source used 
frequently in most human studies [126]. Dietary nitrite intake, on the other hand, comes from 
mainly animal-based products in which nitrite used as food preservatives in processed food, and 
cured meat along with processed grain and cereal products [127, 128].  
In the past, it was believed that nitrate and nitrite content in vegetables was harmful to 
human beings because of an increased risk for cancer and methemoglobinemia. Animal and 
epidemiological studies in 1970s and 1980s have shown that high intake of dietary nitrate was 
associated to the formation of the carcinogenesis compound called nitrosamine in the stomach [126] 
that acts as a precursor for the development of cancer. Therefore, the dosage was strictly limited. 
The World Health Organization (WHO) Expert Committee on Food Additives and the European 
Food Safety Authority (EFSA) set the acceptable daily intake limit of dietary nitrate to 3.7 mg/kg; 
this is equivalent to 4.2 mmol for a 70-kg adult [129] [83]. However, it was pointed out that people 
who consume DASH or vegetarian diet that is rich in nitrate in which the dosage of nitrate 
consumption would result in 1222 mg [130]. This dosage exceeded the WHO acceptable daily 
intake by five times, and have been associated with lower risk of cancers [124, 131]. In regards to 
the studies showing a link between nitrate and nitrite intake in red meat and increased risk of gastric 
or colorectal cancer, most of these associations were relatively weak <2 [128]. A recent study in 
2014 by Dellavalle et al, suggested that colon cancer development is associated with reduced 
antioxidant levels (vitamin C) and not related to high nitrate levels [126, 132]. The WHO Expert 
Committee concluded that epidemiological and human evidence have failed to show any link 
between increasing consumption of nitrate intake and cancer development [133]. Dietary nitrate 
and nitrite naturally interact with the essential nutrients in fruits and vegetables such as vitamin C 
and polyphenols to inhibit the nitrosamine effect [118]. In methemoglobenemia (also referred to as 
“baby blue syndrome”), nitrite reacts with hemoglobin and oxidizes ferrous iron in the heme to 
ferric state to form methemoglobin, and then no longer is able to bind with oxygen [126] . 
Methemoglobenemia was previously observed in infants due to their immature GI enzymatic 
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system and the low gastric acid production capacity. Later on, studies suggested that high nitrite 
was not the cause for methemoglobenemia but fecal bacteria in the well water mixed with infant 
formula was responsible for gut infection and produced NO,which further converted the 
hemoglobin to myoglobin in infants [118, 126]. Recent studies have clarified the safety of 
prolonged intravenous infusion of nitrite in healthy individuals [126]. Thus, evidence about the 
potential toxicity of dietary nitrate and nitrite was overstated [134]. In addition, it was approved 
that dietary nitrate beneficial effects outweigh any risks [133].  
 In the early 20th century, Chinese medicine used inorganic nitrate to treat hypertension, 
while the providers were unaware of the exact mechanism underlying the nitrate effect [83]. 
Recently, cardiovascular research studies are focusing on the mechanistic effects of this component 
among various populations. Interestingly, several primary studies supporting the view of plasma 
levels of bioactive nitrogen oxides (NOx) that were increased after NO3 load, and were associated 
with potential cardioprotective effects [129]. Some examples of inorganic nitrate benefits apart 
from sparing NO signaling and vasodilator actions are improving endothelial function, inhibiting 
platelet aggregation, reducing oxidative stress and improving mitochondrial efficiency, and 
subsequently, improving cardiovascular health [135].   
 Pharmacokinetics of nitrate and nitrite 
 Nitrate and nitrite originate from two sources, endogenous (NO oxidation) and exogenous 
(dietary nitrate) [126]. Administration of dietary NO precursors (independent of NOS pathway) 
rely on sequential reduction of inorganic nitrate to nitrite and then NO to ensure that blood and 
tissue levels of NO and its metabolites are sufficient to mediate NO physiological functions [127, 
136]. Total plasma NO availability reflects the sum of NO generated by endogenous and exogenous 
NO pathways. However, measuring NO levels is inconvenient because the half-life of this molecule 
is very short (i.e. milliseconds) [24]. Under normal and physiological PH and oxygen environment, 
NO is rapidly autoxidized in vivo to form stable compounds, nitrite and nitrate. The average plasma 
concentrations of nitrate and nitrite in healthy individuals is (0.01-0.6 µm), and (20-40 µm) 
respectively [128, 136]. Accumulating evidence supports that the half-life of plasma nitrate is 5-6 
hour  [126, 137] while the half-life of plasma nitrite is about 1-5 minutes [124]. Thereby, plasma 
nitrite plus nitrate (NOx) have been used as a surrogate biomarker to represent NO bioavailability 
for cardiovascular health and other diseases [18]. It is worth noting that plasma and tissue 
concentrations of nitrite and nitrate are inversely associated with cardiovascular risk load including 
age, hypercholesterolemia, hypertension, and other conditions known to reduce NO bioavailability 
[18].  
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 Additionally, plasma levels of nitrate and nitrite are strongly influenced by changes in 
dietary NOx intake [138]. Studies show that the peak in plasma nitrate and nitrite is dose dependent 
[126, 139]. Bolus administration of dietary nitrate in various concentrations increases the 
circulatory markers of NO production dramatically within 25-30 minutes. As an example, 24, 12, 
and 4 mmol of potassium nitrate supplementation increased the endogenous levels of nitrate by 35, 
27, and 7-fold, respectively. Also, plasma nitrite concentrations were raised by 4, 2, and 1.3 fold, 
respectively [140]. Furthermore, sources of dietary nitrate impact pharmacokinetics of plasma 
nitrate [141]. Potassium nitrate supplementation reaches NO3 peak (~1 hr) faster than beetroot juice 
(~2-3hr) at a similar dosing load, and it sustained higher than baseline levels for about 24 hours 
after the last nitrate dose ingestion [142]. Nevertheless, the plasma nitrite attained its peak slower 
than nitrate, after approximately 3 hours post ingestion of dietary nitrate [141]. 
 Exogenous pathway to produce NO (nitrate-nitrite-NO) 
There are two sequential reductions required to convert nitrate to NO via exogenous pathway. First, 
reduction of NO3 to NO2: following an oral nitrate load, dietary nitrate is quickly absorbed from the 
upper gastrointestinal tract into the blood within 30 minutes of consumption, peaking after 1 hour 
[142]. Approximately 75% of the absorbed nitrate excretes in urine while approximately 25% of 
the plasma nitrates are taken up by the saliva and concentrated10-20-fold where it reduced to yield 
nitrite by the presence of oral commensal bacteria [128]. Certain oral anaerobic bacteria possess 
nitrate reductase enzyme to reduce 20% of nitrate to nitrite in saliva under hypoxic condition over 
a few hours [22]. Recent studies have provided evidence about the important role of nitrate reducing 
capacity of oral bacteria  [143, 144]. Mouthwash or overuse of antibiotics that removes commensal 
bacteria could disrupt the exogenous NO production [20]. Moreover, Kapil et al. examined the 
effect of mouthwash treatment for 7 days on healthy individuals, and demonstrated a reduction in 
oral nitrite production by 90% with a decrease in plasma nitrite concentration by 25%, and thereby 
this reduction is associated with an increase in blood pressure [143]. These data suggest that oral 
bacteria is a primary factor for nitrate reduction to nitrite through this pathway, and thereby 
contributes to the systemic levels of nitrites. Second, reduction of NO2 to NO: when swallowed, 
much of saliva nitrite (pKa 3.4) reaches the stomach and gets rapidly protonated to form nitrous 
acid [20, 145]. Subsequently, nitrous acid is further reduced to release large quantities of nitric 
oxide and other oxides of nitrogen [20]. NO production is pH dependent, therefore, low gastric pH 
is the second important factor for nitrite derived NO production. Gastric NO formation could be 
detected in expelled gastric air of healthy volunteers post NO3 –rich lettuce ingestion and were 
significantly higher than those found in orally exhaled air [146]. In addition, pretreatment with 
antacid drugs called proton pump inhibitors (PPI) reduced gastric NO formation by 95% [146]. 
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Some evidence have shown that long-term use of potent antacids medication such as proton pump 
inhibitor may abolish the cardiovascular benefits of dietary nitrate because it could prevent NO 
production [20]. Overall, the main two factors in this exogenous pathway to produce NO are oral 
bacterial and gastric acidic environment. Under hypoxic and acidic condition, unlike the NOS 
dependent pathway, investigators have noticed that this non-enzymatic pathway serves as a backup 
system for NO generation and works more efficient under these conditions in which the classical 
eNOS dependent pathway is dysfunctional/compromised due to NO scavenging by ROS with the 
presence of cardiovascular risk factors [24, 124]. 
 However, it is now known that not all produced nitrite in the gut are converted to NO [23]. 
Some nitrite transport from the gut to the systemic circulation by unknown mechanism of how it 
across the gastric wall [147]. In tissues and circulation, there are numerous enzymatic and non-
enzymatic pathways enhance the bioconversion of nitrite to NO and it is well –recognized that these 
agents participate in acidic and hypoxia conditions [135]. These pathways include xanthine 
oxidoreductase, carbonic anhydrase, aldehyde oxidase, polyphenol, and vitamin C. In the presence 
of vitamin C in gastric environment, additional reactions will occur between nitrite and this potent 
reducing agent to generate NO that can diffuse across the stomach wall and induce local muscle 
relaxation [148]. Published data about the relative contribution of these bioactive agents to generate 
NO is scarce [128].  
 NO2+H+ HNO2 (pKa 3.2-3.4) 
 2HNO2 + vitamin C          2NO + 2H2O+ dehydroASC 
Figure 1-1. Reactions of nitrite reactions 
 Therapeutic effect of dietary nitrate  
a. Dietary nitrate has antioxidant effects 
 Some studies suggest that dietary nitrate supplementation target oxidative stress [149, 150]. 
Animal studies have promising findings about the dietary nitrate effect on different well established 
oxidative stress markers of rats with induced hypertension  [151]and renal ischemia reperfusion 
rats [150]. Nitrate treatments increased the tissue levels of NOx and decreased the levels of 
oxidative stress markers including (malondialdehyde in plasma) and (F2-isoprostanes and 8-
hydroxy-2-deoxyguanosinein in urine) [151] and (NADPH oxidase-mediated O2•− formation in 
bone marrow-derived macrophages) [150]. In agreement with these results, in vitro examination of 
NO2  concentrations (12.5-200µmol/l) prevented myeloperoxide -mediated LDL modification in 
the absence of chloride [152]. Therefore, based on these findings, it could be speculated that dietary 
nitrate possesses antioxidant properties to reduce ROS generation in humans, and this property 
could contribute to preserved NO production from ROS scavengers [149].  
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  However, scarce data are available demonstrating reduced vascular oxidative stress in 
human studies during dietary nitrate supplementation with controversial findings. For example, 
Vulmerurgan et al. (2015) recently found a trend for a greater reduction of oxLDL levels after 
administering 250 ml of beetroot juice (~6 mmol) at 6 weeks in untreated hypercholesterolemia 
[74]. Likewise, Ashor et al., (2016 &2019) examined the acute effect of dietary nitrate on 
endothelial function and oxidative stress markers in two studies for two different populations young 
and older adults with acute hyperglycemia [153], and healthy older adults [154], respectively. In 
the former study, results found that single dose of nitrate supplementation significantly increased 
plasma concentrations of NO metabolites (nitrate and nitrite) and reduced 3- nitrotyrosine as an 
index of oxidative stress (3NT) in older obese adults with acute hyperglycemia compared to 
younger adults. Contradictory to the previous findings, in the latter study, 3NT concentrations were 
not significantly reduced post dietary nitrate supplementation alone. In addition, Larsen et al. 
(2014) reported no changes on plasma oxidative stress biomarkers such as plasma isoprostanes F2 
following administration of inorganic nitrate supplementation for 3 days [155]. Collectively, most 
of these results have been observed with short duration studies of only 1- 3 days intervention and 
in healthy individuals without evidence of oxidative stress, which may make the observation of 
antioxidant properties of dietary nitrate less likely. Many other factors could contribute to this 
contradiction between these studies including dose and duration of nitrate therapy, population 
characteristics, and the use of different oxidative stress biomarkers. Further explorations are 
required to examine whether the use of dietary nitrate as a potential antioxidant source would 
reduce oxidative stress in hypercholesterolemia [74].  
b.  Dietary nitrate improves lipid profile 
 Preclinical studies have shown that inorganic nitrate and nitrite have potential to improve 
dyslipidemia by an unknown mechanism [156-158]. One group investigated the effect of sodium 
nitrite administration on C57Bl/6J mice after they fed them with high cholesterol diet for 3 weeks 
to induce ED and microvascular inflammation. The addition of sodium nitrate to drinking water 
did not change plasma total cholesterol (TC) levels but it reduced triglycerides (TG) levels 
compared to control mice [156]. Another group demonstrated that administration of dietary nitrate 
treatment (0.1 mmol/kg) for 7 weeks reduced visceral fat accumulation and TG levels in aged eNOS 
knock out mice with metabolic syndrome compared to untreated mice [157]. In addition, Khalifi et 
al. (2015) observed a significant improvement in glucose tolerance and the levels of TC, LDL, and 
TG by 22.9%, 54.2%, and 47.6% after nitrate treatment compared to control diabetic rats [149]. 
These findings support the nutrition-based strategies of oral nitrate ingestion against CVD in animal 
models [157]. In human studies, a small clinical study enrolled thirty subjects older than 40 years 
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with high plasma TG levels of >150 mg/dL and at least two cardiovascular risk factors. Findings 
showed a significant increase in plasma nitrate and nitrites, and reduction in elevated TG levels by 
27% after 30 days of a unique formula of nitrate supplementation called Neo40  on empty stomach 
twice a day compared to pre-treatment levels [159]. However, evidence to support beneficial effects 
in humans with hyperlipidemia is lacking, and further human studies will be worthwhile [74] to 
assess whether dietary nitrate with or without other dietary supplements could improve the lipid 
biomarkers [159]. 
c. Nitrate as a NO sparing effect to restore endothelial function  
 In the last two decades, evidence has accumulated to support that ED is responsive to 
dietary interventions and can be partially restored following acute and chronic administration of 
diet-rich inorganic nitrate and/or nitrite [136, 160]. The mechanism underlying vasodilation 
response of nitrate and nitrate is yet to be fully elucidated [128]. The study duration for most 
published studies, that have examined the efficacy of inorganic 𝑁𝑂3 − and beetroot 
supplementation on endothelial function, was generally short ranged from 2 hours to 42 days. The 
majority of acute studies (1.5-4 hours) observed a significant improvement in endothelial function 
as measured by FMD [161-164]. In chronic setting, four published studies examined the nitrate 
intake for a duration of 2-6 weeks. Results showed an improvements in FMD in three different 
populations [74, 140, 165] with no effect was seen in individuals with type 2 diabetes[166].  
 Concerning nitrate benefits on vascular function among the aged population, nitrate 
supplementation has yielded mixed results in older adults who have an age-related decrease in NO 
and higher risk of cardiovascular disease. some studies have seen vascular responsiveness to 
chronic dietary nitrate intake in its various forms (4.5-6 mmol) and were not affected by age in the 
absence of obesity (body mass index ≤30 kg/m2) [140, 165]. Kapil et al. (2015) considered sixty-
eight hypertensive patients ages 18-85 years, stratified to drug naïve and treated patients [140]. 
They were randomly assigned to nitrate or placebo group. Researchers found an increase in plasma 
nitrate and nitrite concentrations by 5.5 and 2.7 fold respectively, and an increase of plasma cGMP 
in both treated and untreated patients. These elevations were associated with reduction in BP, and 
20% improvement in endothelial function as measured by FMD in treated hypertensive patients 
following ingestion of 250 ml beetroot juice (~6.4 mmol daily for 4 weeks compared with nitrate 
depleted beetroot juice (0.007 mmol nitrate). The elevations of plasma NOx were returned to 
baseline level after a 2-week of post-treatment. In line with this study, Rammos et al. (2014) looked 
at eleven normal and overweight elderly volunteers (average age = 63 years) with moderate 
cardiovascular risk [165]. They found that 4 weeks of sodium nitrate (~11.3 mmol of nitrate) 
consumption resulted in a modest increase in FMD of 0.5%, and thus an improvement in endothelial 
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function and reduction in systolic BP in the nitrate intervention group compared to placebo. 
Velmurugan and colleagues (2015) conducted a novel clinical randomized parallel 6-week study 
investigating the effects of inorganic NO3− (~6 mmol nitrate) in the form of beetroot juice on BP 
and endothelial function in untreated hypercholesterolemia patients between 18-80 years old with 
BMI range from 18.5 to 40 kg/m2[74]. Compared to the control group, the beetroot juice group 
showed greater plasma concentrations of NO. Of note, the dietary nitrate group demonstrated 
absolute enhanced blood flow as measured by FMD, and significant reduction in the platelet 
aggregation. In this study, the authors stated that the improvements were related to the duration of 
treatment, not to the dosage. This evidence of this study contradicts the analysis of a systematic 
review in 2014 reporting that greater vascular effect was observed with higher nitrate doses [160]. 
In these studies, the population of interest exhibited at least one cardiovascular risk factors besides 
aging, which might suggest the ability to translate these findings to population at risk of CVD with 
NO insufficiency.  
 Conversely, some evidence suggests that vascular responsiveness in older adults (>52 years 
old) is less sensitive to dietary nitrate compared to younger individuals [167]. In 2013, Gilchrist 
and colleagues demonstrated that 14 days of supplementation with beetroot juice (250 ml, 7.5mmol 
𝑁𝑂3−) in older adults with obesity and type 2 diabetes had no significant effect on FMD or Doppler 
perfusion and therefore did not improve endothelial function [166]. Further, two trials by Ashor et 
al, assessed endothelial function using laser Doppler Flowmetry (LDF) in aged subjects after nitrate 
consumption. In 2015, Ashor et al. administered a 70 ml concentrated beetroot juice with nitrate 
concentrations of ~300-400 mg for three weeks among overweight and obese aged adults with an 
age of 55-67 years. No benefit of daily dietary nitrate was evident in aged-obese adults compared 
to placebo group [168]. Subsequently in 2016, Ashor et al., designed another study to examine the 
acute effect of potassium nitrate intervention (7mg/kg of KNO3) versus its placebo in 10 young and 
10 old obese adults with an age range of 18-70 years old and BMI range of 30-40kg/m2 with acute 
hyperglycemia [153]. The washout period was seven days between the two interventions. Findings 
demonstrated no changes in microvascular blood flow in both groups during acute hyperglycemia. 
A better improvement response in plasma NOx was observed in young adults (31.4 ±1.8 years ) 
compared to older subjects ( 64 ± 1.3 years ) after the ingestion of inorganic nitrate, while a 
significant reduction in oxidative stress biomarkers was shown in older adults. The aforementioned 
studies suggest that obesity and vascular aging may independently modify the reduction of dietary 
nitrate effect. Some investigators have explained age-related factors that could possibly be the 
reasons behind no effect of nitrate supplementation on vascular health are the following: 1) high 
body mass index (>30 kg/m2); 2) low production of gastric acid, or low absorption of vitamin C 
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that may affect NO formation; 3) reduction of oral microflora that may influence the conversion of 
nitrate to nitrite; and/or 4) low sensitivity of vascular smooth muscle cells to the vasodilator NO 
[167, 169]. To conclude, it is currently unknown whether a larger dose and/or a longer duration of 
inorganic nitrate supplementation or both are necessary to have an effect in regressing ROS 
biomarkers and amplifying NO bioavailability to augment cardiovascular effects in older adults 
with underlying cardiovascular diseases such as hypercholesterolemia. Further research is needed 
to determine the effective dosage and duration of beetroot juice for preserving physiological 
function and optimal health for population with advanced aging and at risk of CVD [167]. 
Furthermore, identifying novel dietary nitrate strategies that might improve the oxidative stress and 
ED associated hypercholesterolemia in older adults are required [71]. 
 Introduction to vitamin C (ascorbic acid) 
 Vitamin C known as L-ascorbic acid is an essential nutrient that consists of six-carbon 
compounds [29]. Ascorbic acid is a water-soluble vitamin that human being cannot synthesize it 
endogenously due to lack of enzyme L-glunolactone oxidase [170]. Therefore, vitamin C has to be 
obtained from diet or dietary supplement as tablet or powder. In the diet, it is naturally present in 
various plant-based food sources. Some examples of the vitamin C rich foods are papaya, green 
and red pepper, citrus fruit, cantaloupe, berries, and green leafy vegetables like broccoli, coriander 
[171]. Ascorbic acid plays a crucial role in many biological functions. One of the important roles 
is scavenging free radicals (antioxidant) [172]. Ascorbic acid can be reduced to ascorbate radical 
when it loses the first electron, which has a short half-life ranging with seconds to minutes, and 
then to dehydroacsorbic acid (DHA) after losing the second electron. Both forms are reversibly 
converted back to ascorbic acid [173]. Apart from the antioxidant activity, other benefits of vitamin 
C include serving as a mediator in collagen synthesis, and in protein metabolism, NO restoration, 
vitamin E regeneration, and other benefits that may mitigate the development of AS such as 
decreasing the LDL oxidation, and proliferation of vascular smooth muscle cells [174].  
   The recommended daily allowance (RDA) for adults are 75mg/day for women and 90 
mg/day for men with an upper tolerable limit of 1-2 g/day for both [175]. The normal plasma 
concentration of vitamin C is typically range between 30-60 µM [176]. Plasma vitamin C 
concentrations between 11-28 µmol/L defined as inadequate or marginal vitamin C deficiency, 
while the levels < 11 µmol/L determined as sever deficiency. However, plasma vitamin C levels is 
not a dose dependent as dietary nitrate. At moderate intake of 30-180 mg/day up to 200mg/day, the 
intestine absorbs approximately 70-90 % of vitamin C [177]. An intake of 200mg/day of vitamin 
C is enough to raise plasma concentration of 70-80 µmol/L [175]. However, at very high dose of 
up to 3 g/day of vitamin C, the absorption declines significantly to less than 50% [177]. Results 
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from pharmacokinetics studies have shown that a dose of 1.25 g/day ascorbic acid is sufficient to 
raise the plasma level to 135 micromol/L [172].  
 Some observational studies suggest that western diet lacks of vitamin C [124, 178]. Data 
from 2003-2004 from National Health and Nutrition Examination Survey (NHANES) showed that 
numerous U.S. residents under-consumed vitamin C. About 10% of US adults consumed less than 
30 mg per day of vitamin C, and  suffer from vitamin C deficiency with a plasma level of  <11 
µmol/l [29], and 20% of American populations have marginal vitamin C deficiency [175]. Some 
studies have demonstrated that aging is associated with vitamin C deficiency[179]. The plasma 
concentration of vitamin C of older adults >65 years is 25% less than younger adults [180]. Reduced 
bioavailability with aging is attributed to low absorptive capacity for vitamin C, low vitamin C 
intake, or excessive oxidative stress [180]. Nevertheless, many studies have since looked at the 
favorable outcomes of high vitamin C intake above the RDA throughout the body [181]. The effect 
of vitamin C on oxidative stress, lipid profile, and endothelial function are discussed below.  
 Therapeutic effect of vitamin C  
a. Vitamin C has antioxidant effects  
Vitamin C has been documented to have powerful antioxidant activity [182]. In early 
animal studies, animal models of AS have demonstrated beneficial effect of antioxidant vitamins 
administration [183]. Results from animal studies have been correlated with delayed AS 
progression. These data support the antioxidant hypothesis that dietary supplementation with 
antioxidant vitamins have effect in reducing risk of CHD [183-185]. 
 However, in human studies, abundant data from epidemiologic observational studies as 
well as randomized clinical trials have failed to provide clear-cut indications for antioxidant 
supplementation to combat CVD due to equivocal data [183, 186, 187]. There are extensive 
epidemiological studies that have shown that administration of antioxidant supplements such as 
vitamin C [188, 189], vitamin E, and/or beta-carotene have positive effect on cardiovascular event 
reduction as shown in the Cambridge heart study [190] and Nurses’ Health study [191]. While the 
others failed to confirm this beneficial effect on cardiovascular outcomes as shown in Women’s 
Health Study [192] and the Physicians’ Health Study II [193]. By contrast, randomized clinical 
trials (RCTs) have not established the effect of vitamin C intake on CVD risk [25, 194].  
 Some researchers have explained the reason behind the discrepancy of the results of 
antioxidant vitamins like vitamin C between trials. They suggested possible limitations that might 
reduce the effectiveness of antioxidant vitamins over these studies include differences in subjects’ 
characteristics, the selection dose of antioxidants, and the status of endogenous antioxidant defense 
system [183, 186, 195].  For example, healthy individuals are less likely to respond because of their 
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normal nutritional status. Another example for low-responders is smokers who they might require 
a higher dose of antioxidant vitamin C than others to get rid of the greater oxidative stress in their 
body [25]. other limitation is the failure to measure plasma vitamin C at baseline and after treatment 
in these studies [196]. In addition, the lack of true placebo in diet-related vitamin C studies [195]. 
Subjects taking placebo may continue to consume a high vitamin C diet through the study period 
[195]. Subgroup and meta-regression analyses have recently noted that certain population who 
experience a pro-oxidant state due to the high levels of oxidative stress may benefit more from 
vitamin C supplementation. For example, older adults, obese, patients with higher risk of CVD 
[197], and who have depletion of endogenous antioxidant (e.g. vitamin C deficiency) [25, 188]. 
Future clinical trials should take these limitations into consideration to achieve greater 
physiological response to vitamin C [29].   
 Moreover, it has been shown that vitamin C administration is effective in attenuating LDL 
oxidation. This fact is supported by in vitro studies. Shariat al., (2013) examined the inhibitory 
effect of vitamin C by incubating the LDL with 2 mg/ml MPO in the absence and the presence of 
vitamin C concentration between 50-150mM [198]. Resulted showed that vitamin C inhibited the 
LDL oxidation mediated by myeloperoxidase and increased the lag time of LDL oxidation up to 
2.4 times. Another example of in vitro studies reported that 100 g of cranberries, which has the 
equivalent antioxidant capacity to 1012 mg of vitamin C, resists LDL oxidation [89]. Moreover, 
Das et al., (2006) used different concentrations of vitamin C, 40mMol/L and 80mMol/L, to 
modulate in vitro oxidation of LDL that are isolated from normal and hypercholesterolemic 
subjects[199]. Results showed that higher concentration of vitamin C was required to reduce LDL 
oxidation level from LDL derived from hypercholesterolemic subjects compared to isolated LDL 
from normocholesterolemic subjects. To our knoweledge, most of the aformentioned studies tested 
the susceptility of LDL oxidation in vitro however, few studies were published the vitamin C 
supplementation effect on circulating oxidized LDL in vivo  [200, 201]. Therefore, the 
development of novel strategies to effectively reduce oxLDL itself in vivo is highly anticipated 
[87].  
b. Vitamin C improves blood lipid profile 
Vitamin C supplementation has been shown to be associated with more favorable lipid 
profiles in human observational studies [202]. However, conflicting results were observed in the 
RCTs of vitamin C supplementation on lipid profile [203, 204].  In regard to the mechanisms of 
action, vitamin C acts as a cofactor for the enzyme 7-a-hydroxylase to facilitate the conversion of 
cholesterol to bile acids. This conversion may enhance the expression of LDL receptors to increase 
the uptake of plasma LDL concentration, thereby, lower LDL in circulation [202]. Another possible 
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mechanism to reduce cholesterol concentration is related to the antioxidant protection of vitamin C 
[205]. Vitamin C supplementation causes inhibition of LDL oxidation, which eventually increases 
the LDL uptake by liver and lowers LDL concentration in blood [205]. Two meta-analysis studies 
have looked at the effects of vitamin C on lipids [202, 206]. The first analysis was performed of 13 
trials investigated the effectiveness of vitamin C on blood lipids including total cholesterol, LDL, 
high density lipoprotein (HDL), and TG in adult subjects with hypercholesterolemia. The minimum 
dose of vitamin C supplementation was 500mg/day for duration of at least 3 weeks. Following 
vitamin C administration, results have shown a significant reduction in both LDL and TG levels 
with no significant increase on HDL levels [202]. 
 On the contrary, another meta-analysis study of 40 trials failed to show significant effect 
of vitamin C supplementation on altering lipid profiles [206]. The duration of vitamin C 
intervention in the included studies were > 2 weeks. However, the reduction in cholesterol levels 
was observed only in specific subgroups including younger (< 52 years) adults, subjects with higher 
concentrations of lipids or lower vitamin C at baseline, or individuals at higher CVD risk (e.g. those 
with hypercholesterolemia or dyslipidemia). Because of this contradictory results, further studies 
are warranted to draw conclusions about the effectiveness of vitamin C on hypercholesterolemia 
condition. 
c. Vitamin C has NO sparing effect on endothelial function 
 Vitamin C has been established as a great contributor for the maintenance of the systemic 
NO pool [207]. It is thought that ascorbate plays a beneficial role in endothelial vasodilator 
dysfunction through its ability to decrease oxidative stress biomarkers and spare NO availability 
[207]. Several proposed mechanisms linked with vitamin C modulate vascular tone. These 
mechanisms are 1) scavenging free radical and ROS which prevents them from reacting with NO 
to form peroxynitrite, leading to higher bioactive NO levels [207]; 2) upregulating NOS activity in 
endothelial cells to produce NO through increasing the levels of eNOS cofactor (BH4), inhibiting 
the enzyme arginase, and consequently increasing the L-arginine bioavailability, and/or 
inactivating S-nitrosylation, resulting in more blood flow; 3) acting as a cofactor for eNOS in 
hydroxylation reaction to release NO; 4) decreasing the toxic interaction of oxLDL with endothelial 
cells; 5) preserving the cGMP activity; and 6) enhancing the reduction of nitrite to NO through the 
dietary exogenous pathway of NO, and consequently may potentiate vasodilation [24, 25, 42]. 
Therefore, the antioxidant capabilities and NO probabilities of vitamin C, as shown previously, 
encourage the investigators to examine its potential vasoprotective effects along with nitrate effects 
on clinical and circulatory biomarkers of ED pre and post interventions. 
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 However, clinical trials show inconsistent results with oral vitamin C supplementation on 
endothelial function [25]. Forty-four randomized clinical trials were compared in a systematic 
review [25]. Data analysis reported that two-thirds of these studies had significant improvement on 
endothelial function in response to acute vitamin C supplementation alone (<2 weeks). 
Interestingly, this evidence is limited to older adults and patients with cardio metabolic disorders 
[25]. Acute supplementation with vitamin C had an effect on the vascular function when given to 
individuals with Type II Diabetes (1000 mg) for 3 days measured by FMD [208] and to healthy 
subjects exposed to glucose load to induce ED (1000mg) for 10 days measured by forearm blood 
flow [209]. Taken together, the current studies published the effect of vitamin C on endothelial 
function in patients with metabolic syndrome or hypercholestrolemia are few [25]. A metanalysis 
review of 44 trials found a greater effect of vitamin C on endothelial function was demonestrated 
in experimental induced ED, and patients with diabetes or heart failure, or AS [188]. However, 
conflicting results were found in studies that measured the effect of vitamin C administration on 
endothelial function in hypertensive, smokers, or healthy subjects [210]. Additionally, investigators 
concluded that the improvement of endothelial function is affected by vitamin C dose and 
unaffected by the study design, duration, and route of administration [25]. According to vitamin C 
dose, data from meta-analysis of 9 cohort trials showed that 700 mg/day or higher, which exceeded 
the RDA, elicited substantial improvements in endothelial function and were associated with a 25% 
reduction in CHD risk [211]. 
 Moreover, aging was linked strongly to the modifying effect of long-term vitamin C 
supplementation for more than 2 weeks on endothelial function [188]. Antioxidant vitamin C 
supplementation profoundly restored ED in older individual (56 years or older), but no benefit was 
shown in younger (age <56) or healthy individuals with no ED [18, 188]. The explanation for 
achieving greater benefits of vitamin C supplementation in older adults may be because they were 
more likely to have inadequate intake of vitamin C, their requirements were higher than young 
adults in order to remove oxidative stress that resulted from aging, or due to their lower baseline 
vitamin C status and higher oxidative stress [25, 195]. It has been proposed that systemic or 
localized ascorbate deficiency and oxidative stress generates ED in various diseases and conditions 
and is rapidly treatable with ascorbate repletion [207, 212]. Therefore, these data suggests that 
elevation of plasma vitamin C may restore endothelial function and enhance NO bioavailability 
[213]. Overall, although the antioxidants therapy of vitamin C and dietary nitrate are attributed to 
improvement in endothelial function separately, paucity data has been examined the combination 
effect of these compounds to augment endothelial function among CVD population [22]. Future 
studies exploring the combined effect of dietry nitrate and vitamin C on vascular function and used 
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biomarkers to assess patients risk may identify effects of these compounds on cardiovascular 
health.  
 Nitrate-nutrient interaction 
As mentioned earlier, when NOS is impaired, NO can be produced via the non-enzymatic 
NO pathway. One of the factors that is likely increase nitrate effectiveness is the ingestion with 
additive or synergistic compunds such as polyphenols or antioxidants (e.g. vitamin C ) [169].  To 
our knowledge, there is limited evidence towards the combined effects of deitary nitrate and these 
compounds on cardiovascular health, particularly, endothelial function. Polyphenol and dietary 
nitrate as a combination have been studied to look at their ability to augment NO status and 
endothelial function. In one study, the acute effectiveness of flavonoid as an additive to improve 
NO status, endothelial function, and blood pressure was tested in randomized controlled crossover 
study with healthy men and women [162]. Subjects were divided into four groups: receiving 
control, flavanoid-rich apple, nitrate-rich spinach, apple +spinach (nitrate and flavonoid in 
combination). The washout period was 1 week. They found that nitrate and flavonoid had lower 
systolic blood pressure when provided together compared to other groups. However, all treatment 
groups have higher NO status and FMD compared with control group. Another similar cross-over 
study examined the interaction between flavanols and dietary nitrate on endothelial function at low 
and high doses in healthy subjects [161]. Measurments were taken to determine FMD, intragastric 
NO formation, and plasma NO metabolites. Additive effects were observed when nitrate and 
flavanol was consumed together on endothelial function. An  increase in NO formation in the 
stomach and a significant improvement in FMD response by 1% was observed 1 hour post-
consumption of  low intake of flavanols (2.7 mg/kg) in combination with inorganic nitrate (3 
mg/kg) compared to higher intake. These data suggest additive effects between dietary nitrate and 
NO-releasing compounds which may exert beneficial cardiovascular effects. 
With regard to the interaction between dietary nitrate and vitamin C,  previous research 
focused on the individual cause- and- effect of dietary nitrate and vitamin C with vascular function 
improvement and biomarkers of cardiovascular risk [214, 215]. Studies support the notion that 
vitamin C enhances the efficiency of the enzymatic and non-enzymatic NO pathways as a potential 
way to preserve endothelial function in patients whom NO insufficiency and high concentration of 
ROS may be more pronounced [25]. These data support the hypothesis that introducing vitamin C 
with inorganic nitrate may enhance the formation of NO from dietary nitrate and thus increase the 
efficiency of NO bioavailability in endothelial cells. Thereby, possibly improve compensatory 
vasodilation in patients with impaired endothelial function [99, 160]. The possibility that 
simultaneous consumption of dietary nitrate and vitamin C could have an additive or even a 
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synergistic effect on cardiovascular health is derived from the observation that both nutritional 
constituents augment NO production via different mechanisms and from studies showing that 
vitamin C  catalyzes the conversion/reduction of acidified nitrite to NO in the gastric acidic 
environment [22, 39, 216, 217]. Astudy of Dejam etal. (2007) Supported a role of vitamin C as an 
intravascular reductant for nitrite-induced vasodilation of the human forearm [218]. They found 
that vitamin C improved the forearm blood flow modestly by 10% when it co-infused 
intrabrachially with nitrite copmared to nitrite alone.  
Recently in 2017, Ashor et al., demonstrated for the first time the potential of a beneficial 
synergistic interaction between inorganic NO3- (7mg/kg) and vitamin C (20mg/kg) on vascular 
outcomes. These dosage are corresponded to 150-250 g of nitrate and 1400 mg of vitamin C in 70 
kg adult person. Results showed a significant decrease in arterial stifness measured by pulse wave 
velocity (PWV) (PWV:-2.0 m/s, P=0.02) and mean arterial BP (-2.6 mmHg, P=0.03) following a 
single dose of dietary nitrate combined with vitamin C at lower doses in healthy aged adult 
volunteers compared to vitamin C and nitrate alone [154]. However, the interaction of these 
compounds was not investigated in longer studies nor in vulnerable population with impaired 
vascular function. Based on this evidence, there is a reason to believe that supplemental vitamin C 
could have the potential to complement dietary nitrate effects for augmenting the NO pool, and 
amplifying vascular-protective benefits of dietary nitrate if introduced for longer duration [19]. Its 
important to take into consideration that the vascular responses to dietary nitrate coupled with 
vitamin C may not be the same among healthy compared to obese old individuals with higher risk 
of cardiovascular diseases (hyperlipidemia). Additionally, further studies are warranted to examine 
the optimal dosing regimen and study duration that maximize beneficial effects, if any, on 
endothelial function and oxidative stress biomarkers. Moreover, it is interesting to investigate 
whether the interaction between these could 1) promote addtive interaction resulting in greater 
increase in NO availability and further reduction in oxidative stress biomarkers, 2) achieve greater 
effects on markers of CVDs – including endothelial function– than do these dietary agents given 
individually [216].  
 Summary 
Endothelial dysfunction and oxLDL are the main two hallmarks involved in the 
development and progression of AS and are associated with most cardiovascular risk factors 
including hypercholesterolemia. Hypercholesterolemia associated oxidative stress production and 
oxLDL have been found to reduce NO bioavailability and then promote ED. ED serves as an 
independent predictor of CVD and it can be treated by dietary therapeutic interventions. Therefore, 
studies targeting NO pathway to improve overall vascular health, as monitored by measures of 
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vascular response to post reactive hyperemia with non-invasive technique, and blood biomarkers 
should be of great interest. Evidence from clinical studies has suggested a novel nutrition 
intervention called dietary nitrate that serves to restore NO insufficiency through the nitrate-nitrite-
NO pathway, thereby improve vascular health. While most beneficial effects of exogenous nitrate 
ingestion were mainly found in healthy and hypertensive populations, few have looked at the usage 
of dietary nitrate for hypercholesterolemia population. Although NO insufficiency is the hallmark 
feature of ED, it is unknown whether the dietary nitrate intervention for endothelial function with 
hypertension and healthy individuals will be suitable for other population like 
hypercholesterolemia. Four weeks of dietary nitrate supplementation were sufficient to produce 
favorable changes in endothelial function. However, there is no study published yet has examined 
the dietary nitrate effect on endothelial function using PAT assessment. Studies have shown that 
the antioxidant vitamin C enhances non-enzymatic conversion of inorganic nitrate to NO. Dietary 
nitrate and vitamin C are powerful nutrient constituents that have been studied independently in 
augmenting NO pool, reducing oxidative stress, and even lipid profile, but their combined effect 
requires further studies to elucidate potential effects on the cardiovascular system. To date, only 
one recent study of Ashor et al that investigated the acute potential of synergistic effect of dietary 
nitrate with vitamin C on vascular health in healthy individuals, yet no study has evaluated the 
efficacy of administering these anions together for longer duration nor in older adults with impaired 
vascular function. While the impact of dietary nitrate on vascular health is greater in young 
population, evidence of stronger response to vitamin C intervention > 2 weeks was observed in 
older adults ≥ 56 years of age and those with higher BMI compared to young adults. Overall, further 
studies to develop optimal effective dose and duration of dietary nitrate therapy combined with 
vitamin C could be of great benefit to explore the potential additive effects of these compounds on 
endothelial function and oxidative stress biomarkers in older adults with cardiovascular risk factors. 
 Scope of dissertation 
 Innovation  
  This dissertation is the first study examining the effect of dietary nitrate on endothelial 
function and cardiovascular biomarker with the use of 4 innovative approaches. (1) Combined 
supplement intervention examines the additive effect of antioxidants and NO properties of dietary 
nitrate with vitamin C supplementation in normal and obese older adults with impaired endothelial 
function. (2) Study technique: uses PAT method to examine the sensitivity of PAT hyperemic 
response to the therapeutic dietary nitrate intervention. The evidence supporting the vascular 
benefits of dietary nitrate using endoPAT method is understudied. (3) Plasma biomarkers: uses the 
ratio of oxLDL/NOx to assess ED. The effect of dietary nitrate on this ratio has not been 
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investigated [60]. (4) Combined clinical parameters with plasma biomarkers: This study assessed 
endothelial function from two perspective methods, noninvasive method (PAT) with the relevant 
biomarkers (oxLDL/NOx ratio). 
 Study purpose 
The purpose of this study is to investigate whether adding vitamin C will complement the 
benefits of dietary nitrate supplementation and yield a robust effect on endothelial function 
compared to dietary nitrate supplementation alone. We anticipate that the addition of vitamin C 
will enhance the effects of dietary nitrate, resulting in the augmentation of the cumulative NO pools 
and inducing a greater improvement in vascular function and reduction in oxidative stress 
biomarkers as determined by RHI values and oxLDL to NOx ratio. 
 Study hypothesis 
 Our central hypothesis is that co-supplementation of nitrate and vitamin C for four weeks 
will improve blood biomarkers and clinical measures of endothelial vascular function over-time as 
determined by oxLDL/NOx ratio and RHI, respectively, compared to the provision of dietary 
nitrate supplementation alone. 
 Study aims 
Specific Aim 1: Examine the combined effects of dietary nitrate and vitamin C supplementation on 
a clinical biomarker of vascular endothelial function (Peripheral Artery Tonometry) compared to 
dietary nitrate alone. 
Specific Aim 2: Examine the combined effects of dietary nitrate and vitamin C supplementation on 
plasma biomarkers of oxidative stress and endothelial dysfunction (oxidized LDL/NOx ratio) 
compared to dietary nitrate alone. 
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 MATERIALS AND METHODS 
2.1 Experiment design  
 The purpose of this study was to examine the efficacy of beetroot juice, with or without 
vitamin C supplementation on endothelial function and oxidative stress outcomes in older subjects 
between 50-70 years old with high cholesterol (> 130 mg/dL), and not on statin medication. This 
was a randomized; double blinded, placebo-controlled, crossover study. The study consisted of one 
4-week intervention period and one 4-week placebo control period separated by a 2-week washout 
as shown in (Figure 2-1). 4 weeks intervention was hypothesized to be sufficient to detect changes 
in endothelial function based on previous work that considering either dietary nitrate intervention 
[140, 165] to produce favorable changes for vascular health in subjects at risk of CVD. In addition, 
this washout period was chosen based on previous work that documented this period was 
successfully returned NO metabolites and vitamin C to baseline level [219-221]. Subjects visited 
the laboratory a total of 4 times to complete study measures: during the screening visit/ baseline 1 
(week 0), endpoint 1 (week 4), baseline 2 (week 6), and endpoint 2 (week 10). The timeline of the 
study visits along with the associated study measures at each visit is shown in (Table 2-1). Height 
and weight, endothelial function, BP, assessment of plasma vitamin C, nitric oxide species, 
oxidized LDL, lipid profile and dietary intake were measured pre and pose each intervention. All 
testing procedures were performed following a 12 hour overnight fast.  
 Before implementing the study, The University of Kentucky Institutional Review Board 
approved this study. Written informed consent was obtained from all subjects prior to participation 
at their first visit. Study data were saved in charts and in an electric data capture tool (REDCAP). 
REDCAP is a web application used to capture datasets for research studies.   
 Subjects characteristics (inclusion and exclusion criteria) 
 Males and post-menopausal females between 50-70 years old were recruited to participate. 
This age group was selected because older adults are more prone to have endothelial dysfunction 
[222], and the percent of hypercholesterolemia among adults aged 55 and over was higher than 
younger adults in both sexes [223]. The inclusion criteria included subjects with a body mass index 
(BMI) of 18.5–34.9 kg/m2, who were non-smokers, with high cholesterol levels (low-density 
lipoprotein cholesterol >130 mg/dl), and without a history of lipid pharmacological treatment 
(statin). A BMI of 34.9 kg/m2 was used as a cut off for this study because obesity might modify 
dietary nitrate response [153, 166]. We want to eliminate confounding factors with our sample size 
and elucidate whether dietary nitrate will have an effect on endothelial function with normal BMI 
to obese class I older adults. 
 
 
31 
  Exclusion criteria included evidence of overt atherosclerotic disease (i.e., documented 
medical history of coronary artery disease, peripheral artery disease, cardiovascular disease, and 
stroke). Additional exclusion criteria included any surgery or medical history that could confound 
study results, such as a history of bowel resection, rheumatoid arthritis, inflammatory bowel 
disease, celiac disease, diabetes, uncontrolled hypertension (systolic blood pressure >160 mm Hg 
or diastolic blood pressure >100 mm Hg), controlled hypertension on clonidine medication, or 
tobacco use in the past month. Subjects with BMI less than 18.5 Kg/m2 or greater than 34.9 Kg/m2 
were not eligible to take part in the study. Moreover, subjects were ineligible if they had been 
diagnosed with the following medical conditions such as active cancer, severe anemia (Hb < 
10mg/dL), hepatic or renal disease, heart failure, or finger deformities. In addition, HIV-positive 
patients on combination antiretroviral therapy because of potential pharmacokinetic interactions 
with beetroot juice were excluded. Subjects were also excluded if they reported taking any form of 
hormone replacement therapy (estrogens, progesterone, and testosterone), multivitamin 
supplements that provides >100% of RDA, or any of the following medications that attenuate 
nitrate conversion to NO: proton pump inhibitors (PPI) and antibiotics. Finally, subjects who 
consumed greater than 6 drinks of alcohol (any form) per week, performed structured resistance or 
aerobic training for more than 1-hour four times per week, or participated in other clinical 
intervention within the previous 30 days were excluded from the study. Exclusion criteria were 
specified to eliminate different conditions or diseases because the effects of dietary nitrate may not 
uniformly affect endothelial function due to these various conditions, so the current work could 
focus on hypercholesterolemia- related endothelial dysfunction in older adults. In addition, they 
were asked to avoid using the mouthwash before and throughout the study duration. In addition, 
enrolled subjects were advised to consume low- vitamin C diet throughout the study. They were 
provided at the beginning of the study with a list of high vitamin C foods/fortified foods to avoid 
during the study. 
 Subjects screening procedures and description of study measures 
 Subjects were identified and recruited through the medical centers of the University of 
Kentucky campus using an IRB approved recruitment flyer (Appendix 1.a) that were distributed to 
the physicians’ offices of outpatient internal medicine clinic at the University of Kentucky, and 
internet and social media (using UK and departmental/lab pages), Family medicine at Turfland 
clinic. Other sources for recruitment were internet and social media (using UK Facebook page), 
and UK HC television screens found in high-traffic hallways. The study consisted of two screening 
visits and three laboratory visits to complete study measures:  
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Screening visit stage 1: The first screening stage consisted of a screening interview 
followed by a vascular screening visit. This stage of the screening process was coordinated by a 
trained graduate student and included one of the following: 1) face-to face interview with potential 
study subjects visiting the outpatient clinics to gauge volunteer interest followed by assessing 
height/weight for BMI, and checking inclusion and exclusion criteria with brief questions about 
medical history to check for potential eligibility. 2) Phone screening for potential subjects recruited 
from ResearchMatch and social media were included same screening questions as the face- to face 
interview. Potentially eligible subjects who passed the first stage of screening were asked to sign 
the informed consent form before inclusion in the trial. Following the informed consent process, 
subjects were scheduled for the second stage of screening.  
A medical history questionnaire (Appendix. B) about current alcohol and smoking status, 
physical activity, specific chronic illnesses or medical; conditions that could confound the study 
results, past bowel surgeries, or any evidence of overt atherosclerosis disease. In addition, this 
questionnaire documented if subjects were currently seeing their primary healthcare provider for 
any reason, and if they were on any of the following: prescribing drugs, and over the counter 
medications including dietary supplements, hormonal replacement therapies, antibiotics, and 
antacid medications. Potential subjects who are on proton pump inhibitor (PPI) medications were 
asked to discuss switching to an H2 blocker medication with their primary care provider and then 
reported back to the study team.  
Screening visit stage 2: this second stage determined the final eligibility with a 
confirmation of poor endothelial function RHI≤ 2 by non-invasive vascular testing (PAT). This 
vascular screening visit occurred within a month after the screening visit stage 1 (Figure 2-1). 
According to the study measures, it entailed three processes: 1) anthropometrics and vascular 
testing 2) blood draw, 3) 24-hour dietary recalls were completed by the research coordinator and 
graduate research assistant in the nutrition program. All study visits were conducted at Center for 
Clinical and Translational Science (CCTS) clinic. Each visit to the UK campus lasted for 60-75 
minutes. The following are the timeline for each study visit.  
 Baseline visit 1: Once screening stage 2 was completed, and the study volunteer was 
eligible to take part in the study based on initial screening results, vascular testing during the 
screening visit 2 served as part of the baseline measures on the first day of intervention 1. During 
the same visit, the study coordinator asked the CCTS nurse to draw a blood sample for measuring 
baseline plasma levels of vitamin C and NO metabolites concentrations (NO3, NO2, and NO), lipid 
profile, and oxidized LDL. Subjects who did not pass the vascular testing in the screening stage 
were thanked for their interest and participation in our screening visits.  
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 Baseline visit 2: Following the washout period on the first day of intervention 2, subjects 
returned to the clinic for repeating study measures. All baseline 1 testing procedures were repeated, 
except the blood measures for plasma NO metabolites and vitamin C levels. After that, the alternate 
treatment were distributed and the subjects were asked to start taking them from this day.  
 Endpoint study visits (Endpoint 1 and Endpoint 2): To determine the efficacy of the 
intervention, all baseline 1 testing procedures outlined above were repeated at the end of each study 
intervention (one day after the last intake of dietary supplements or placebo). 
 Blinding and randomization 
 On baseline testing days after baseline testing complete, subjects were assigned randomly 
to start with either inorganic nitrate + vitamin C, or inorganic nitrate + vitamin C placebo. 
Subsequently, a washout period of two weeks preceded the alternate treatment as shown in Figure 
2-1. The randomization was conducted using the Investigational Drug Service (IDS) at our 
institution, which assisted with storage, supply management, quality control, and transfer of the 
study supplement. Random numbers that corresponded to each of the study subject were generated 
by statistical software and individually placed in sealed envelopes for treatment assignment. 
Vitamin C and its placebo packaging were identified by the letter “A” or “B”, and only IDS staff 
was unmasked to supplement assignment.   
 Dietary supplement interventions   
 Supplemental nitrate (NO3) 
The nitrate supplement was provided in the form of commercial beetroot juice (Sport Beet 
IT shot, Heartbeet Ltd) for all subjects. Sport Beet IT was a concentrated beetroot juice (70ml) that 
delivered on average 300-400mg of inorganic nitrate. This product was made from using 
conventional non-organic concentrated beetroot juice. The product had no added flavors. This 
supplement was served either cold or at room temperature. Subjects were asked to consume one 
shot of Sport Beet IT per day. Subjects were asked to not mix beetroot juice with anything and 
particularly citrus, because the low pH of citrus juice can convert nitrite (pKa 3.4) to NO prior to 
consumption and thereby reduce the efficacy of the product. All subjects were encouraged to 
consume the supplements regularly during the morning hours between 7 and 11 am each day if 
possible and drink it as fast as possible within 2-3 minutes so it is all in the stomach at the same 
time. Additionally, subjects were asked to avoid chewing gum after drinking beetroot juice for a 
minimum of 3 hours.  
 Vitamin C and matching placebo 
Vitamin C and the placebo were provided as supplement capsules. The preparation and 
labeling of the vitamin C and its placebo were performed by the IDS in such a way that both pills 
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were identical in shape, color, and size to ensure adequate blinding of both subjects and investigator. 
All investigational supplements were stored in a locked cabinet with limited access at room 
temperature and were protected from light until distribution. Vitamin C supplements were either 
active capsules that contained 500 mg of Nature Made product in each or corn starch placebo 
capsules. Subjects were asked to consume a total of 1000 mg of vitamin C every day. This 1000 
mg dose was divided into two capsules; each capsule delivered 500 mg of vitamin C. The dose of 
vitamin C was based on previous work by Ashor et. al who reported in meta-analysis study that 
700 mg of vitamin C or higher elicited an improvement in endothelial function [25].  
 Based on subjects’ supplement assignment, supplements were distributed to subjects to 
self-administer at home with breakfast. However, the first dose was administered in the clinic right 
after the study measures have been completed. Subjects were asked to consume supplements in the 
morning every day during the four-week study period, except for the test days and washout weeks. 
Aligned with recommendation from Rodriguez-Mateos et al., subjects were asked to consume the 
concentrated beetroot juice with breakfast meals, and then 2 vitamin C capsules or placebo at the 
same time one-hour post beetroot juice supplementation. One-hour provides enough time to permit 
dietary nitrate to be absorbed completely and then re-entered the entero-salivary circulation and 
thereby maximize salivary nitrite levels in the saliva at time of vitamin C ingestion (Rodriguez-
Mateos et al., 2015). If the subject reported skipping breakfast or forgetting to take the supplements 
with breakfast, they were instructed to ingest the supplements at lunchtime. At each baseline visit, 
subjects received a 14-day supply of supplements that contain of 30 pills and 15 bottles of beet 
juice (2 pills/day + 2 extra pills, and 1 BRJ/day + 1 extra bottle). Study subjects were asked to 
retain all the used and unused study packaging to turn in to the study coordinator at their next 
scheduled supply distribution. The redistribution of supplements occurred every two weeks to 
ensure that subjects remained in contact with the study team every two weeks.  Subjects were asked 
to record the daily date and time of supplement consumption with the amount consumed.  
 Study procedures 
 Clinical assessment 
 Measurements for height and weight were collected for each subject at each visit using 
digital wall-mount stadiometer (DETECTO 3P, Webb City, MO) and Tanita 800S scale (Tokyo, 
Japan) at the CCTS. Subjects were instructed to remove shoes and not hold anything before 
stepping on the scale to determine their height and weight. The study coordinator calibrated the 
scale to zero and then asked the subject to step on the scale to record their body mass in kilograms 
(kg). Further, subjects were instructed to stand up against the wall of the stadiometer as the 
coordinator lowered the headpiece to touch firmly on top of the subject’s head and recorded to 
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measure height in centimeters (cm). BMI was calculated using the formula of numerical values of 
weight and height as weight (kg)/ height (meters2).   
 Blood pressure measurements were obtained with automatic BP cuff 5-10 minutes before 
each vascular testing visit [224]. Blood pressure measurements were taken from the non-dominant 
arm in a relaxed position with arm rested at the sides of the subject to determine the supra-systolic 
blood pressure for endoPAT. Subjects were asked to not cross their feet during the blood pressure 
measures and the study coordinator recorded the systolic and diastolic values (mmHg).  
 Vascular testing 
 Endothelial health was assessed using endoPAT-2000 device (Itamar Medical, Caesarea, 
Israel) to measure digital pulse wave amplitude (PWA) pre and post flow stimulus. We focused on 
assessing vascular function as a reliable outcome measure described in previous cardiovascular 
intervention studies [78, 95]. Since the decline of endothelium-derived NO bioavailability is 
reflected by impaired PAT vascular responses [78].  
 Prior to each vascular testing, including the screening visit stage 2, subjects were asked to 
do the following: 1) consume a low-nitrate diet for 48 hours to control diet variation between study 
subjects [219]. Study personnel provided potential subjects with reference table that clarifies all 
high nitrate sources in the screening visit stage #1; 2) refrain for 24 hours from taking anti-
hypertensive agents and long- acting vasoactive medications including steroids, beta-blockers, 
antacid, anticoagulants, calcium channel blockers, angiotensin converting enzyme inhibitors (ACE-
inhibitors), and aspirin; 3) abstain from consuming alcoholic beverages, coffee, a high fat diet, 
chewing gum; 4) and abstain from any strenuous exercise for 24 hours before study visit [74]; 5) 
fast overnight for 12 hours before morning study visits [99]. The presence of the aforementioned 
medications and dietary compounds has been shown to influence endothelium dependent NO 
vasodilation and may affect the study outcomes. 
 EndoPAT tests occurred at CCTS for each visit at approximately 10 AM. Measures were 
performed in a temperature-controlled room (70–75°F [21–24°C]) and the subject was asked to lie 
in a supine position before the procedure [99]. This test lasted for 20 minutes. The endoPAT device 
measured pulsatile changes of the occlusion and control arms via finger probe plethysmography. A 
blood pressure measurement with a standard electronic BP cuff was taken, and then a manual blood 
pressure cuff was placed on the upper arm of the non-dominant hand (occlusion arm) to start 
performing PAT measure. Then, two probes plethysmography that lined with sensitive balloons 
were placed on the both index fingers of each hand and inflated. The metal tips inside these probes 
record/assess changes of pulse volume amplitude (PWA) at the fingertip in response to reactive 
hyperemia [225]. Reactive hyperemia acts as a stimulus to release the vasodilator, NO. The PAT 
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endothelial test consisted of three phases: baseline (pre occlusion), occlusion, and post occlusion 
(hyperemia). Subjects were asked to stay still as possible during the entire testing period. Following 
a 10 min quiet rest period, the blood pressure cuff was inflated to suprasystolic pressures by adding 
at least 60 mmHG above systolic blood pressure for five minutes during occlusion then the cuff 
deflated quickly and endoPAT device continued recording reactive hyperemia response for five 
minutes [95, 224]. The RHI ratio of the study arm was instantly calculated automatically by 
dividing post-occlusion PWA to the pre-occlusion value of PWA of the same arm, normalized to 
the control arm, and then multiplied by baseline correction factor to determine RHI (Figure 2-2). 
RHI greater than 2 is indicative of normal endothelial function and RHI< 2 is considered poor 
endothelial function. Validation studies reported that lower RHI is associated with clinical 
population of cardiovascular risk factors.  
 Blood sampling and analysis 
 Fasting blood samples were drawn by trained staff at University of Kentucky’s CCTS 
immediately following the vascular testing at all visits. Venous blood samples were collected in 
three specific tubes with three different colored tops from all subjects during the morning of the 
testing days to measure plasma vitamin C (red top), nitrate/ nitrite content and oxidized LDL 
(purple top), and lipid profile (green top). Blood specimen were taken mostly from the antecubital 
vein but if arm vein attempt was not successful, we used the dorsal surface of the wrist. A 21 gauge 
x ¾” butterfly needle was used for our blood draws. The volume of each tube was as follows: lipid 
panel: 3 mL, vitamin C: 4 mL, and NO metabolites and oxLDL tube: 3 mL. The latter tube 
containing ethylenediaminetetraacetic acid (EDTA) and was centrifuged immediately, and then 
transferred to three 0.5mL cryo tubes to analyze the relevant samples. Sample storage and analysis 
were completed using standard procedures by CCTS staff. The plasma was separated from the 
whole blood by centrifugation at 20°C for 10 minutes and then stabilized with metaphosphoric acid. 
Plasma samples were stored at −80°C for analysis at end study. The university Biospecimens Core 
of the CCTS and UK clinical lab processed all blood samples and completed all analyses. 
Chemiluminesence/colorimetric assay, high performance liquid chromatography (HPLC), roche 
analyzers a cobas 311 or cobas 702, and sandwich enzyme-linked immunosorbant assays (ELISA) 
with the antibody 4E6 were used to asses circulating plasma levels of NO metabolites, ascorbate 
concentrations, lipid profile, and OxLDL respectively.   
 Dietary assessment 
 Dietary intake was monitored throughout the study by collecting three- day food diaries in 
each study period to examine the extent to which differences in dietary intake influenced study 
outcomes. Upon enrollment in the study, subjects were instructed to maintain their lifestyle 
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including physical activity, and diet throughout the study duration as these factors have been shown 
to influence endothelial function [226-228]. Subjects were asked to keep track of what they 
consumed including all food, beverages and snacks for three non-consecutive days, two weekdays 
and one weekend. Trained nutrition graduate students in dietary assessment conducted an interview 
by phone to complete the three 24-hr dietary recalls per subject during the midpoint of each 
interventional period (week 2&3, and week 8&9). The interviewer asked subjects to report their 
food and beverage intake consumed throughout the interview. The interviewer recorded all details 
about food and beverage items including portion size, methods of preparations, ingredients, and 
brand name if known. In addition, subjects were asked about their use of any dietary supplements 
and to provide a description of their composition and dose. Data were recorded using Nutrition 
Data System for Research software (NDSR version 2017, Minneapolis, MN). This method is a 
standardized recall strategy designed to improve recall accuracy [229-231].  
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Figure 2-1. Schematic representation of the study design 
NO3: inorganic nitrate provided in concentrated beetroot juice dietary supplement; (N): inorganic 
nitrate and vitamin C placebo; (NC): inorganic nitrate and active vitamin C 
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Table 2-1. Timeline of visits and associated measures 
BL: baseline; EP: endpoint. 
  
 
Study 
Measures 
Screening Visits Weeks
1-4 
Visit 2 
(EP1) 
  
Visit 3 
(BL2) 
Weeks
7-10 
Visit 4 
(EP2) screening1 Screening2 
/BL1 
Anthropometri
c measures  
 X  X X  X 
Inclusion/ 
exclusion 
screening 
X       
Medical history 
questionnaire  
X       
Blood pressure 
and Vascular 
testing 
 X  X X  X 
Blood draw  X  X X  X 
24-hr dietary 
recalls 
  X   X  
Supplement 
distribution  
 X X  X X  
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Figure 2-2.PAT testing showing normal (A) and abnormal (B) hyperemia response. 
A healthy blood vessel dilates notably in response to ischemic stimulus as shown in figure (A) and 
the PWA increased post cuff deflation compared to baseline. An artery with endothelial dysfunction 
lacks the ability to release sufficient NO resulting in low reactive hyperemia response post-deflation 
as shown in figure (B). 
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 AIM 1 
 Abstract 
Introduction: Endothelial dysfunction (ED) serves as a marker of atherosclerotic risk. The key 
mechanism of ED is limited nitric oxide (NO) bioavailability. Dietary nitrate represents an 
alternative source of NO and improves endothelial function through its sequential reduction to 
nitrite and then NO. It is believed that vitamin C contributes to nitrite reduction in the gastric cavity 
to boost NO production. The combined effect of providing both dietary supplements on ED is 
relatively unexplored. 
Purpose: The aim of this study was to compare the effect of inorganic nitrate in the form of 
concentrated beetroot juice (CBJ) with and without vitamin C on ED as measured by the reactive 
hyperemia peripheral artery tonometry (RH-PAT) in subjects at risk for cardiovascular disease.  
Methods: Untreated hypercholesterolemic Subjects, aged 50-70 years with RHI ≤2 were enrolled 
in this randomized crossover double-blind study. Two 4-week interventions were separated by a 2-
week washout. Subjects were assigned to daily CBJ (70mls) with 1000 mg of vitamin C (NC) 
(sequence1; N-NC) or CBJ with matched placebo (N) (sequence2; NC-N), then switched to 
alternate treatment. The change in endothelial function was assessed using the reactive hyperemia 
index (RHI) at 4 weeks compared to the study baseline for each intervention, and then the score 
change between the two interventions was compared (RHI change of N treatment vs RHI change 
of NC treatment). Secondary outcome measures included plasma vitamin C concentration and 
plasma NO metabolites as indices of NO production.  
Results: Eighteen subjects aged 53-70 years completed the study. No differences in RHI change 
score (N: 0.21±0.46; NC: 0.20±0.67; p> 0.05) were observed following 4 weeks of each 
intervention. Eight out of 18 subjects responded with greater improvement in RHI following NC 
(High-responders: 0.73±0.52; Low-responders: -0.32±0.23; p<0.001) compared to N. It was found 
that subjects who showed a better response in RHI after NC entered the study with mean baseline 
RHI of <1.67 than those who less respond with greater mean RHI scores >1.67 (1.23; n=8 v. 1.75; 
n=8; p=0.02). Significant differences were observed between overall treatment in the mean change 
of plasma nitrate (N: 78.64±15 μmol/L; NC: 128.66±29 μmol/L; p<0.001) and nitrite N: 0.08±0.02 
μmol/L; NC: 0.04±0.03 μmol/L; p=0.03). Likewise, the mean change of plasma vitamin C was 
greater following 4 weeks of NC treatment compared to N treatment (N: -0.14±0.53 mg/dL; NC: 
0.45±0.66 mg/dL; p<0.001).  
Conclusions: Vitamin C, when combined with inorganic nitrate for 4 weeks promotes an additive 
effect on the NO pool and may potentiate greater improvements in endothelial function in subjects 
with significant endothelial dysfunction compared to inorganic nitrate supplementation alone.  
 
 
42 
 Introduction  
 Vascular endothelium produces several vasoactive substances to maintain vascular 
homeostasis [232]. One of the most important mediators that promotes vaso-relaxation is nitric 
oxide (NO)[233]. Endothelial dysfunction (ED) represents a well-established response to 
cardiovascular risk factors such as aging and hypercholesterolemia, and acts as a primary driver of 
atherosclerosis (AS) development [39, 42]. ED is characterized by a reduction in the bioavailability 
of the vasodilator NO and an enhancement of oxidative stress production resulting in an impairment 
of endothelium-dependent vasodilatation [45]. Endothelial function can be assessed by measuring 
the vascular response to physiological stimuli, reactive hyperemia, in the coronary and peripheral 
arteries [42]. Flow mediated dilation (FMD) is the most prevalent method utilized in most clinical 
trials to assess for ED in conduit arteries because it is non-invasive technique and principally 
mediated by endothelium-derived NO [106]. An alternative technique with high reproducibility 
called reactive hyperemia peripheral artery tonometry (RH-PAT), based on the same principle as 
FMD, has emerged for assessing peripheral endothelial function using fingertip probes and has 
resulted in associating ED with cardiovascular risk factors in three studies [33, 99, 104]. Unlike 
FMD, RH-PAT testing is more affordable, easily trained, and operator independent as automated 
calculation of reactive hyperemia index (RHI) [96].  
In order to mitigate the deleterious effect of ED and further reduce the risk of major cardiovascular 
disease (CVD) events among vulnerable populations, we must better understand the role of 
modifiable lifestyle factors on vascular health. Modifiable lifestyle factors including healthful 
dietary choices [94, 162, 209] and exercise [227, 228] have been shown to positively restore NO 
bioavailability and further ameliorate ED. In epidemiological studies, high fruit and vegetable 
intake has been associated with lower risk of CVD [122, 234]. Bioactive constituents present in 
fruits and vegetables may be responsible for these cardioprotective effects. For example, vitamin 
C and E [121], potassium [122], and other bioactive components may produce protective 
cardiovascular effects such as inorganic nitrate [123]. Supplementation with inorganic nitrates or 
with vitamin C (ascorbic acid) has been shown to augment NO production via different 
mechanisms, which in turn, is thought to increase vasodilation and improve endothelial integrity 
[25, 160, 235]. Inorganic nitrate is a dietary NO precursor derived from natural sources such as 
green leafy vegetables and beets and relies on sequential reduction to nitrite and then NO through 
entero-salivary circulation [20, 123, 236]. This non-enzymatic pathway serves as a backup system 
for NO generation and works more efficiently under acidic and hypoxic conditions than the 
endothelial nitric oxide synthase (eNOS) dependent pathway. The classical eNOS pathway is often 
dysfunctional in the presence of cardiovascular risk factors [24, 124]. Under hypoxic and acidic 
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conditions in the blood and gastric lumen, the presence of vitamin C may augment the reduction of 
nitrite to NO [236].  The interaction between nitrate and vitamin C has been recently described in 
the literature and has indicated that that vitamin C acts as an enhancer to catalyze the conversion 
of acidified nitrite to NO, thus, increasing the NO pool [147, 218, 236-238].  
NO2 – + H+ → HNO2  
2 HNO2 + vitamin C → 2 • NO + dehydroascorbic acid + 2 H2O 
Therefore, the combination of dietary nitrate and vitamin C is a potentially promising 
dietary supplement strategy to combat ED associated CVRFs. However, evidence describing their 
combined effect on cardiovascular health, particularly, endothelial function is limited. Recently, 
synergistic acute effects were observed when a single dose of inorganic NO3- was administered in 
combination with vitamin C on vascular outcomes [154]. Results showed improvements in arterial 
stiffness as measured by pulse wave velocity (PWV), heart rate variability (HRV) indices, the 
cofactor BH4 compared to nitrate or vitamin C given separately. However, this combination did 
not improve endothelial function in all groups as measured by post-occlusion reactive hyperemia 
(PORH). It is not yet known if longer duration studies designed to combine these dietary 
supplements would serve to improve endothelial function outcomes over time in vulnerable 
populations. 
We aimed to examine whether the co-administration of vitamin C and nitrate for a longer 
duration would yield an additive effect on endothelial function. The purpose of this study was to 
investigate the combined effect of a 4 week vitamin C and dietary nitrate supplementation regimen 
on post-occlusion reactive hyperemia, a clinical biomarker of vascular endothelial function as 
measured by PAT ratio, compared to nitrate supplementation alone. On the basis of their 
complementary mode of action to augment NO and improve endothelial function, we hypothesize 
that that 4 weeks co-administration of inorganic NO3- and vitamin C would elicit a greater 
improvement in endothelial function as determined by reactive hyperemia index (RHI) as a result 
of changes in plasma levels of NO metabolites compared to nitrate alone.   
 Methods and materials 
 Subjects 
 Male and female non-smokers with a body mass index (BMI) range of (18.5-34.9 kg/m2) 
between the ages of 50 and 70 years of age with high LDL concentrations (>130 mg/dL) were 
enrolled in the study. Subjects were not eligible if receiving lipid lowering therapy, multivitamin 
supplements exceeding >100% of recommended daily allowance (RDA), or on medications at the 
time of screening that would interfere with the study outcomes (e.g. hormone replacement therapy, 
proton pump inhibitors (PPI) and antibiotics). Additional exclusion criteria were history of 
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cardiovascular disease, diabetes mellitus, chronic inflammatory disease, celiac disease, 
uncontrolled hypertension (systolic blood pressure >160 mm Hg or diastolic blood pressure >100 
mm Hg), controlled hypertension on clonidine medication, hepatic or renal disease, and active 
cancer. Moreover, subjects who consumed greater than 6 servings of alcohol per week, performed 
structured resistance or aerobic training for more than 1-hour four times per week, or participated 
in other clinical interventions within the previous 30 days were excluded from the study. Final 
enrollment decisions were contingent upon vascular testing results (RHI is  2). 
  The study was approved by the university Institutional Review Board, and the informed 
written consent was obtained from all subjects prior to engaging in baseline measures. All 
institutional and governmental regulations concerning the use of human volunteers were followed 
during this research. All study visits were conducted in the Center for Clinical and Translational 
Sciences (CCTS), University of Kentucky, from February 2019 to September 2019.  
  Design and randomization 
 This was a 10 week randomized, cross-over, double-blinded, placebo-controlled study. 
This study was designed to compare the magnitude changes in RHI (primary outcome), plasma 
nitrate and nitrite levels as biomarkers for NO (secondary outcome), and plasma vitamin C 
following the 4-week treatment of inorganic nitrate with vitamin C placebo (N) and inorganic 
nitrate combined with vitamin C (NC).  Eligible subjects were randomized to receive either 
treatment (N) or treatment (NC) for 4 weeks (period1), and subjects were then crossed over to the 
alternate treatment for another 4 weeks (period 2). There was a 2-week washout at crossover. 
Throughout the intervention periods, enrolled subjects were advised to consume low- vitamin C 
diet throughout the study. They were provided at the beginning of the study with a list of high 
vitamin C foods/fortified foods to avoid during the study. 
 Dietary supplementation intervention 
The nitrate supplement was provided to all subjects in the form of commercial beetroot juice 
beverage (Sport Beet IT shot, Heartbeet Ltd). Sport Beet IT was a concentrated beetroot juice (CBJ) 
(70ml) that delivered an average of 300-400mg of inorganic nitrate. Vitamin C and the placebo 
were provided as supplement capsules. The study coordinator was blinded to the treatment 
assignment and the randomization was conducted by investigational Drug service (IDS) at 
University of Kentucky, which prepared the list of randomization treatment sequence and then 
provided to the study coordinator with the treatment allocation. The preparation and labeling of the 
vitamin C and its placebo were performed in such a way that both pills were identical in shape, 
color, and size to ensure adequate blinding of both subjects and investigator. Vitamin C 
supplements were either active capsules that contained 500 mg of ascorbic acid (Nature Made ®) 
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or corn starch placebo capsules. The dose of vitamin C provided in this study was based on previous 
work by Ashor et. al who reported in meta-analysis study that 700 mg of vitamin C or higher elicited 
an improvement in endothelial function [25]. The study coordinator instructed subjects to self-
administer CBJ for 7 days a week at the same time by mouth during the morning hours and then 
consume 2 pills (1000 mg of vitamin C or placebo) one hour later.  
 Supplement adherence was assessed by counting the unused pills and beer juice bottles. 
Subjects were asked to return any unused CBJ bottles and vitamin C pills at the following endpoint 
visits of each intervention for pill counts.  
 Study protocol 
Screening visits: The study consisted of two screening visits: a screening interview followed by a 
vascular screening visit. At screening visit stage 1, phone screening or a face-to face interview was 
performed with potential study subjects to gauge subject’s interest followed by assessing 
height/weight for BMI and checking inclusion and exclusion criteria with brief questions about 
medical history to assess eligibility. At screening visit stage 2, a non-invasive vascular testing using 
PAT test was employed to determine final eligibility for subject selection: only subjects with RHI 
score 2 were included in the study. This visit served as part of the baseline measures for enrolled 
subjects and other study measures were assessed once vascular testing was completed.  
Study visits: Subjects completed 4 visits at the beginning and the end of each interventional period 
for anthropometric measures, blood pressure, vascular testing, and for blood collection as indicated 
in the subject timeline (Figure 3-1). Vascular function was defined as measures of RHI ratio 
(primary outcome). Biochemical markers of ED included in this study were plasma nitrate/nitrite 
as indices of NO production and plasma vitamin C (secondary outcome). Prior to each visits, 
including screening visit stage 2, subjects were asked to perform the following to prepare for 
vascular testing: 1) consume a low-nitrate diet for 48 hours to control diet variation between study 
subjects [219]; 2) refrain from taking anti-hypertensive agents and long- acting vasoactive 
medications including steroids, beta-blockers, antacid, anticoagulants, calcium channel blockers, 
angiotensin converting enzyme inhibitors (ACE-inhibitors), and aspirin for 24 hours; 3) abstain 
from consuming alcoholic beverages, coffee, high fat foods, chewing gum; 4) abstain from any 
strenuous exercise for 24 hours [74]; and 5) fast overnight for 12 hours before morning study visit 
[99].  
Subjects were instructed to maintain their usual dietary patterns throughout the duration 
of the study and dietary intake was assessed via 24-hr dietary recall. Three 24-hours dietary 
recalls were collected and analyzed using Nutrition Data System for Research (NDSR, Version  
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2019, University of Minnesota, Minneapolis, MN, USA) at midpoint of each interventional 
period, covering 1 weekend and 2 weekdays for a total of 6 recalls. 
 
Figure 3-1. Schematic representation of the study design. NO3= inorganic nitrate provided 
in concentrated beetroot juice dietary supplement 
 
 Vascular testing using peripheral artery tonometry 
 Endothelial health in peripheral arteries was assessed using EndoPAT-2000 device with 
finger plytheysmographic probes (Itamar Medical, Caesarea, Israel) to measure finger pulse wave 
amplitude (PWA) changes pre and post flow stimulus. EndoPAT tests occurred at approximately 
10 AM for each visit. Measures were performed in a temperature-controlled room (70–75°F [21–
24°C]) and the subject was asked to lie in a supine position for the procedure [99]. To start 
performing PAT measure, a blood pressure measurement (BP) with a standard electronic BP cuff 
was taken, and then a manual BP cuff was placed on the upper arm of the non-dominant hand 
(occlusion arm). The PAT endothelial test consisted of three phases: baseline (pre occlusion), 
occlusion, and post occlusion (hyperemia). Subjects were asked to stay still as possible during the 
entire testing period. Following a 10 min quiet rest period, the blood pressure cuff was inflated to 
suprasystolic pressures by adding at least 60 mmHG above systolic BP for five minutes then the 
cuff was deflated quickly and EndoPAT device continued recording pulse wave response for five 
minutes [95, 224]. The RHI ratio of the study arm was calculated automatically by dividing post-
occlusion PWA to the pre-occlusion value of PWA of the same arm, normalized to the control arm, 
and then multiplied by baseline correction factor to determine RHI score.  
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 Blood sampling and analysis 
 Fasting blood samples were drawn by trained staff at University of Kentucky’s CCTS 
immediately following the vascular testing at all visits. Venous blood samples were collected in 
three specific tubes with three different colored tops from all subjects during the morning of the 
testing days to measure plasma vitamin C (red top), nitrate/ nitrite content (purple top). Plasma 
samples were stored at −80°C for analysis at end study. Plasma nitrate and nitrites were analyzed 
using the commercial assay kits according to the manufacturer’s instructions. Nitrate/Nitrite were 
measured by Parameter assay kit KGE001. Nitrate/nitrite are measured by the Griess Reaction 
[239], a reaction that produces a diazonium ion which subsequently couples to amine 1-
naphthylamine to produce a red-violet color (absorbance @ 540-570 nM). Plasma vitamin C 
concentrations were analyzed using HPLC.  
 Statistical analysis 
 Using the nQuery Advisor program, sample size calculations were based on the work of 
Kwak et al. (2012) who assessed endothelial function by PAT measure in subjects with newly 
diagnosed type 2 diabetes [116]. Based on these data, nineteen subjects were needed for 80% power 
with a two-sided p-value of ≤ 0.05.  
 Statistical analysis was performed using Statistical Package for Social Sciences (SPSS) 
software (version 22, IBM, Armonk, NY). This study was designed to detect significant differences 
in RHI between the two treatments (NC vs N). Distribution of continuous variables were examined 
by Shapiro-Wilk test. Within treatment group, comparisons at baseline and 4-weeks for each 
treatment were conducted by Paired Student t-tests (for normally distributed data) and Wilcoxon 
signed rank-test test (for non-normally distributed data) for two period data separately. Changes in 
measures over the 4-week period were assessed by calculating the difference between the pre and 
post-intervention measures. Between treatment group, the treatment effect was evaluated by the 
two-sided one-sample t-test which is based on the mean of the differences between the two changes 
for each pair () [240]. An independent sample t-test was used to assess the changes in RHI between 
high-responders and low-responders. Additionally, based on work by Wellek et al. [241] we 
examined whether there were any carryover effects from one treatment period to another. Linear 
mixed models were used for secondary analysis to assess the potential interaction effect of variables 
such as BMI and BP medication, sex, and age with the dependent variables in the two treatments. 
Pearson and Spearman correlations were used to assess the relationship between the dependent 
variables. Spearman correlations were used for variables that were not normally distributed. Data 
are presented as mean ± standard deviation in tables and mean ± standard error of the mean in 
figures. 
 
 
48 
 Results 
 Subjects  
A total of 162 subjects were assessed for eligibility and 23 eligible subjects were 
randomized. Of these, 18 completed both interventions and all study visits (Figure 3-2). Subjects 
had a mean age of 594 years and a BMI of 28.33 kg/m2. Thirteen subjects were normal to 
overweight with a BMI range from 22.5 to 29.9 kg/m2. Five subjects were obese (class I) with a 
BMI range (30.8 to 34.4 kg/m2). There were no significant differences in baseline characteristics 
between the two treatment groups (sequence 1: N-NC and sequence 2: NC-N) (Table 3-1). No 
significant changes in body mass index were observed between the two treatment periods.  
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Figure 3-2. Consort Diagram 
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 Table 3-1. Baseline Characteristics 
 
BMI: body mass index; BP: blood pressure; NO3: nitrate; NO2: nitrite; NO: nitric oxide; RHI: 
reactive hyperemia index. (sequence1; N-NC): subjects were assigned to randomly start with 
inorganic supplementation alone in period 1 and then crossed over to inorganic nitrate with vitamin 
C in period 2. (sequence2; NC-N): start with inorganic supplementation with vitamin C in period 
1 and then crossed over to inorganic nitrate supplementation alone in period 1. Quantitative 
variables were described as the meanSD. (P≤0.05, student t-test, Wilcoxon Rank-Sum test, and 
fisher exact test). Values were not significantly different between groups at baseline. 
 Endothelial function 
Two subjects who started NC treatment were excluded from RHI statistical analysis due to poor 
RHI signals at endpoint. For our primary outcome of comparing differences between our two 
treatment groups (N vs NC), there were no significant differences in RHI change (N treatment: 
0.21±0.46; NC treatment: 0.20±0.67; p> 0.05). No evidence of carryover effect was observed from 
Variables Treatment N 
(sequence1; N-NC) 
Treatment NC 
(sequence2; NC-N) 
Total 
 (n=9) (n=9) (n=18) 
Male sex, n (%) 3(33%) 4(44%) 7(39%) 
Age (years) 58 ±3 59 ±5 59±4 
BMI (kg/m2) 29.6±3.1 27.1±3.0 28.3±3.2 
Systolic BP 
(mmHg) 
130±15 125±11 127.5±13.5 
Diastolic BP 
(mmHg) 
84±10 81±6 85.5±8.2 
Subjects on BP 
medications, n (%) 
3 (33.3%) 3 (33.3%) 6 (33.3%) 
Plasma vitamin C 
(mg/dL) 
0.73±0.4 0.88±0.5 0.81±0.41 
Plasma NO3 
(μmol/L) 
13.4±5.3 18.5±8.5 16.0±7.3 
Plasma NO2 
(μmol/L) 
0.44±0.2 0.46 ±0.3 0.45±0.25 
RHI  1.55±0.3 1.66±0.3 1.60±0.3 
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one treatment course to the other (p=0.64). Within treatment group comparisons for both treatment 
N (p=0.09) and treatment NC (p=0.24) revealed that the RHI score over time did not significantly 
change (Figure 3-3A). In addition, no notable interactions were observed between any of the 
dependent and independent variables. 
We observed that the RHI of eight subjects with mean RHI baseline value of (1.23± 0.43) 
responded to the NC treatment greater than the N treatment (mean 1.75± 0.32). Following these 
observations, subjects were grouped into “high-responders” and “low-responders” based on their 
RHI response to NC treatment. High-responders demonstrated significant increases in RHI score 
pre to post NC treatment intervention (1.23± 0.43 to 1.96 ±0.53; p<0.01), while the low-responders 
had a significant decrease in RHI after the NC treatment intervention (1.75± 0.32 to 1.43 ±0.29; 
p<0.01). The RHI change in responders was 0.73±0.52, while the RHI change in less-responders 
was -0.32±0.23; p<0.001. The change of RHI over time following NC treatment between high-
responders and low-responders is found in Figure 3-4.  
 Plasma biomarkers  
a.  Nitrate and nitrite levels 
Significant differences were observed in the mean change of plasma nitrate (N: 78.64±15 μmol/L; 
NC: 128.66±29 μmol/L; p< 0.01) and nitrite (N: 0.08±0.02 μmol/L; NC: 0.04±0.03 μmol/L; 
p=0.03) between both treatment groups. Within treatment group comparison showed that the 
endpoint plasma nitrate levels were significantly increased compared to baseline (p<0.001) 
(Figure3- 3B&C). Likewise, the endpoint plasma nitrite levels were significantly increased after 
N (p=0.006) but did not increase after 4 weeks of NC (p=0.23). Secondary correlational analysis 
indicated that post-supplementation changes in plasma vitamin C correlated significantly with 
changes in plasma nitrate levels following NC treatment (r=0.49, p=0.044). In addition, RHI change 
between N and NC was inversely related to changes in plasma nitrite (r=-0.68, p<0.001), but not 
with plasma nitrate (r=0.07, p=0.81).   
b.  Vitamin C concentrations 
One subject who started with N treatment was excluded from statistical analysis due to missing 
data at endpoint. There was a significant difference in plasma vitamin C change between the 
treatments (N: -0.14±0.53 mg/dL; NC: 0.45±0.66 mg/dL; p<0.001). Within treatment group 
comparison showed that plasma vitamin C concentrations increased significantly over time 
following 4-week administration of NC (Figure3-3D).  
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 Supplement adherence 
Overall, subject reported adherence for taking dietary supplements in both interventional periods 
was 99.7% in period1 and 99% in period2 for CBJ, and 98% for period1 and 97.5% in period2 for 
vitamin C.  
 Dietary patterns 
Analyses of three 24-hour dietary recalls indicated that no significant differences in nutrient intake 
and dietary pattern (Table 4-2). Three subjects were removed from the analysis because their 
dietary recalls were missed in period 2. 
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Table 3-2. Nutrient Intake and Dietary Patterns. 
 N Treatment  
(n=15) 
NC Treatment 
(n=15) 
P-value 
Energy (Kcal) 1757.2±505.2 1571.8±537.7 0.17 
Protein (g) 65.6 ± 16.2 62.8±15.1 0.49 
Carbohydrate (g) 202.9 ± 81.0 177.6±88.7 0.26 
Fat (g) 80.9 ± 31.9 69.9±23.9 0.12 
MUFA (g) 27.5 ± 11.6 26.1±9.7 0.58 
PUFA (g) 17.7 ± 10.2 13.8±5.2 0.13 
SFA (g) 29.2±14.0 24.0±10.7 0.057 
Vitamin C (mg) 46.5±23.9 59.6±49.4 0.23 
Vitamin E (mg) 10.3±5.4 9.8±3.5 0.69 
Alcohol (g) 3.4±6.1 2.6±4.4 0.24 
Caffeine (mg) 244.1±132.2 243.6±120.9 0.98 
Dietary patterns    
Dark-Green 
vegetables 
Servings/day 
0.56±0.7 0.59±0.7 0.92 
Cured meat 
Servings/day 
0.05±0.1 0.07±0.1 0.22 
 
MUFA: mono-unsaturated fatty acids; PUFA: Poly-unsaturated fatty acids; SFA: Saturated fatty 
acids. P value were calculated from paired t-tests between N vs. NC. N Treatment: inorganic nitrate-
rich beet juice and vitamin C placebo or NC Treatment: inorganic nitrate-rich beet juice and active 
vitamin C (1000mg). Values were not significantly different between treatment groups. Values are 
presented as mean ± SD.  
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Figure 3-3.Endothelial function measurements in response to 4 weeks interventions of dietary 
nitrate supplements with and without vitamin C. 
RHI score (n=16) (A), NO3: plasma nitrate (n=18) (B), NO2: Plasma nitrite (n=18) (C), and plasma 
vitamin C (n=17) (D) before (dark gray panel) and after 4-weeks of supplementation (white panel) 
with (N) Treatment: inorganic nitrate-rich beet juice and vitamin C placebo or (NC) Treatment: 
inorganic nitrate-rich beet juice and active vitamin C (1000mg). Values represent means ± SEM. 
Data were analyzed using paired t-test for RHI and vitamin C, and Wilcoxon-test for plasma nitrate 
and nitrite levels, *p ≤0.05. = mean difference between the two changes for each pair. Data were 
analyzed using one sample t-test, †P<0.05.  
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Figure 3-4. Change of RHI over time following NC treatment between high-responders and 
low-responders 
RHI score response was compared between high-responders (n=8) and low-responders (n=8) 
before and after 4 weeks of NC treatment.  NC: inorganic nitrate -rich beet juice and active vitamin 
C (1000mg). RHI: Reactive hyperemia index. Subjects with greater change score in NC were 
defined as high responders. Data were analyzed using independent sample t-test to assess RHI 
baseline score between high-responders and low-responders, *p ≤0.05. 
  Discussion 
 Vascular testing using RHI 
The primary finding from this study was that there were no significant differences in 
endothelial function, as measured by RHI, between NC and N treatment groups. These findings do 
not support the first half of our hypothesis that 4 weeks co-administration of inorganic NO3- and 
vitamin C would elicit a greater improvement in endothelial function as determined by reactive 
hyperemia index (RHI) compared to nitrate alone. Previous work has shown a positive 
improvement in endothelial function following 4-6 weeks administration of inorganic nitrate in 
subjects with CVRFs [74, 140, 165]. All of these RCTs reported improvements in vascular 
reactivity following dietary interventions of nitrate have assessed endothelial function via FMD, a 
reliable method for the measurement of NO-mediated endothelial function [96, 111]. Improvements 
in FMD reported in these studies were achieved through an increase in NO bioavailability [242].  
The absence of a significant change in RHI in the present study may have many 
explanations. Like FMD, RH-PAT measures are inversely related with traditional CVRFs; 
1
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however, previous studies have shown that correlations between FMD and RH-PAT measurements 
are controversial [97, 98, 103, 113, 224, 243]. It has been proposed that a key difference between 
these two measurement techniques is partially due to the fact that the RH-PAT method is in part 
dependent on NO [108] and different vasodilation regulators such as prostaglandins, adenosine, 
and other non-endothelium-dependent mediators underlying the post-reactive hyperemia response 
[107, 244]. As PAT measures do not solely assess NO mediated endothelial function, it has been 
suggested that PAT may not be sensitive enough to detect the influence of lifestyle modifications 
on microvascular beds [97, 107, 224].  This is in line with former work conducted by Wray et al. 
[213] that demonstrated significant improvement in endothelial dependent -vasodilation via FMD 
in conduit arteries following an acute-administration of an antioxidant cocktail but failed to show 
detectable changes when measured by reactive hyperemia in different vessels (resistance vessels) 
of elderly subjects. Moreover, it was suggested by Wray et al. that their vitamin C intervention 
could possibly improve endothelial function without influencing the microvascular function [213]. 
It has been postulated that endothelial improvement following vitamin C supplementation occurs 
through a reduction of oxidative stress that subsequently improves bioavailability of NO. However, 
the current study did not look at changes in oxidative stress associated with improvements in RHI 
and therefore cannot support this evidence. 
An additional explanation for no alterations in RHI could be that EndoPAT manufacture 
guidelines established a threshold value for ED of <1.67 to define endothelial dysfunction [245]. 
An RHI value below 1.67 was found to have 80% sensitivity and 85% specificity to detect subjects 
with coronary endothelial dysfunction [246]. Therefore, another possible explanation for why no 
improvements were seen in our primary outcome could be that the baseline RHI values of some 
subjects were >1.67. Endothelial function scores greater than this cut point value may be less 
responsive to improvements in endothelial function. In our secondary subgroup analyses, it was 
shown that the eight “high responder” subjects who showed an individual increase in RHI following 
NC treatment (~60% improvements from baseline) had a baseline mean of RHI score below the 
threshold value of 1.67. Fifty percent of the high responders achieved an increase in RHI to normal 
or above normal values, while the other eight subjects (defined as low-responders), had a baseline 
mean of RHI >1.67. Our findings were supported by two different studies that noticed an 
improvement in RHI was substantial following dietary interventions in subjects with impaired 
endothelial dysfunction of <1.67 RHI value at baseline [114, 247]. For example, Maki et al. (2013)  
[247] demonstrated a significant improvement in RHI values following 5 weeks of consuming low-
fat dairy products compared with low-fat non-dairy products among subgroup analyses of  
hypertensive subjects with RHI less than 1.67. Similarly, Kim and colleagues divided subjects into 
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two groups based on their initial levels of RHI using 1.67 as a cut value. They demonstrated that 
lycopene intervention for 8 weeks significantly increased RHI in subjects with impaired endothelial 
function at baseline [114]. Furthermore, although it is important to note that adherence data for 
vitamin C supplementation was excellent in all subjects, we were not able to determine if all 
subjects took vitamin C exactly one hour following CBJ consumption. Proper timing of vitamin C 
ingestion 1 hour after the nitrate dosing is important to permit adequate nitrate to enter the 
enterosalivary circulation, thereby maximizing the reduction of nitrite to NO in the gastric cavity 
as vitamin C consumed [161]. Improper timing of vitamin C intake with respect to CBJ intake may 
partially explain our results of no significant differences in the treatments combination versus 
nitrate alone. Our findings may suggest that responders adhered with the timing of vitamin C 
ingestion more than less-responders. 
 NO metabolites and vitamin C  
In the current study nitrite and nitrate were used as surrogate measures of vascular NO 
bioavailability [18]. As expected, our NC intervention produce significant differences in plasma 
NO3 and NO2 levels compared to nitrate supplementation alone. Additionally, plasma vitamin C 
was significantly increased after 4 weeks of NC treatment. Our findings were inconsistent with 
recent work by Ashor et al., [154] who found no modifying effect of vitamin C on plasma nitrate 
and nitrite following  supplementation with an acute single dose of potassium nitrate (5.1-8.7 
mmol) combined with vitamin C (20mg/kg) in healthy individuals. This disparity in findings could 
be due to the study duration and the differences in the populations studied. Our results suggest that 
the addition of vitamin C to the consumption of inorganic nitrate supplementation for a longer 
duration of 4-weeks yielded a substantially greater improvement in circulatory markers of 
endothelial function in older adults with hypercholesterolemia. Continued supplementation of 
dietary nitrate and vitamin C in the present study elevated plasma nitrate to 8.8 fold in systemic 
circulation, while dietary nitrate alone caused a 6.0 fold increase in plasma nitrate after 4-weeks of 
intervention. When comparing our findings with a recent study that examined a similar nitrate 
supplement dosage (~6mmol) on hypercholesterolemia for 6 weeks [74], our work demonstrated 
that combined NC administration resulted in an 8.8 fold increase compared to a 7.5 fold increase 
following dietary nitrate alone after a longer duration of 6 weeks. These findings support the 
second-half of our hypothesis that exogenous vitamin C supplementation modifies the effect of 
dietary nitrate resulting in greater changes in plasma levels of NO metabolites compared to nitrate 
alone. Furthermore, the significant increase of plasma nitrate levels from baseline within each 
treatment group with or without vitamin C confirmed an excellent adherence with CBJ and 
supported what have been demonstrated in literature that plasma nitrate and nitrite are strongly 
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influenced by changes in dietary nitrate intake and the exogenous pathway NO3-NO2- NO is a good 
precursor for augmenting systemic NO production in subjects with CVRFs [74, 248].  
When assessing plasma nitrite levels within each treatment group, we showed that 4 weeks of 
inorganic nitrate supplementation alone increased the nitrite circulatory levels to 1.2 fold which 
reflected that nitrite can be derived from dietary nitrate intake, while vitamin C combined with 
nitrate supplementation produced no significant changes in plasma nitrite over time. These findings 
following NC treatment could be due to the increased reduction of nitrite to NO and other nitrogen 
oxygen species through the exogenous pathway in the acidic environment of stomach with the 
presence of vitamin C resulted in substantial augmentation of NO and less availability of nitrite to 
be absorbed into circulatory system [162]. The second explanation could be due to the auto-
oxidation of nitrite to nitrate as a stable end product of NO in a circulatory system [249, 250]. 
Another potential possibility for the observed plasma nitrite not increased significantly as the N 
treatment could be that vitamin C scavenges superoxide radicals, thus, increasing the bioavailability 
of the NO produced from nitrate [161].  
 Strengths and limitations 
To our knowledge, this was the first study to examine the relationship between RHI and inorganic 
nitrate supplementation individually and in combination with vitamin C supplementation. This was 
also the first study investigating the therapeutic co-effect of inorganic nitrate and vitamin C 
supplementation among subjects at risk of CVD. This work has many strengths including the 
crossover study design, strict inclusion and exclusion criteria, and high supplement adherence. An 
additional strength is that dietary intake appeared to be consistent between the two interventions. 
There are also limitations in this work that should be taken into considerations for the future trials. 
There is wide inter-individual variation in RHI scores in response to study supplementation that is 
largely due to our small sample size. Small sample size may have limited our ability to observe 
significant differences between treatments or potential interactions between the dependent and 
independent variables when analyzing our outcomes. An additional explanation for the wide inter-
individual variation of our PAT results may be the sensitivity of probes to movements which may 
have resulted in excessive signal noise exposure. Another limitation is that not all the subjects 
studied had a high prevalence of endothelial dysfunction. Subjects were selected based on their 
LDL concentrations of >130 mg/dL and their baseline RHI score of <2. The results of a subgroup 
subjects with ED (RHI≤1.67) suggest a significant association between NC and vascular measure. 
These observations deserve further attention in future studies given the potential additive impact of 
combined supplementation on restoring vascular health in subjects with impaired endothelial 
function. In addition, it is thought that FMD response is dependent on endothelium- derived NO 
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[242]. Therefore, examine the combined effect on endothelial function in large clinical trials using 
appropriate gold standard method like FMD to evaluate the treatment efficacy would draw a firm 
conclusion whether vitamin C could modify the effect of dietary nitrate supplementation on clinical 
measures of endothelial function.  
 Conclusion 
The current study did not find a significant change in RHI between treatment groups among older 
adults with hypercholesterolemia, though a subgroup of subjects with low RHI at baseline have 
significant improvements in RHI. The addition of vitamin C to dietary nitrate may have resulted in 
the greater augmentation of systematic nitric oxide synthesis from the exogenous NO pathway. 
These improvements may positively influence the downstream pathways affected by NO 
production and improve endothelial function.   
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 AIM 2 
 Abstract 
Introduction: Oxidative stress is a key mediator contributing in the promotion of endothelial 
dysfunction (ED) and atherosclerosis (AS), which may be counteracted by preserving endothelial 
nitric oxide (NO). Evidence has shown inorganic nitrate supplementation can improve NO 
bioavailability. It is conceivable that vitamin C may enhance the exogenous NO production through 
stepwise reduction of nitrate to nitrite to NO. Purpose: Our aim was to compare the change in 
plasma oxidized low density lipoprotein (oxLDL) to the sum of NO metabolites (NOx) ratio 
following the combined treatment of vitamin C and inorganic nitrate (NC) compared to inorganic 
nitrate alone (N).  
Methods: Male and female subjects, aged 50-70 years with low-density lipoprotein (LDL) >130 
mg/dL, and not treated with statin drugs were included in this randomized double-blind crossover 
study. Subjects were randomly assigned to start with either N (concentrated beetroot juice (CBJ) 
and placebo) (sequence1; N-NC) for 4 weeks or NC (CBJ with vitamin C (1000 mg)) (sequence2; 
NC-N) for 4 weeks in period1 and then crossed over to the alternate treatment for another 4 weeks 
in period2. At baseline and 4 weeks of each treatment, vascular NO bioavailability was assessed 
by plasma NO nitrate and nitrite (NOx) while oxidative stress was measured by plasma oxLDL to 
compare the magnitude change of oxLDL/NOx ratio between the two treatment groups. Plasma 
lipid profiles served as secondary outcome measures.  
Results: NC treatment reduced oxLDL/NOx ratio compared to N (N: -3.97±2.83U/L; NC: -
4.29±3.07U/L; p= 0.02). When analyzing the elements of the ratio separately, mean plasma oxLDL 
change was not different between treatments (N: -1.08±9.8 U/L; NC: -6.07±9.1 U/L; p= 0.19) 
although the reduction in oxLDL was evident over time for NC only (p=0.01). The mean plasma 
NOx change was significantly different between treatments (N: 94.24±82.9 μmol/L; NC: 
128.70±123.5 μmol/L; p=0.01) and within group improvements in NOx were evident in both 
treatments (p<0.05). Four-weeks of NC treatment elicited significant reductions in the mean change 
of circulating concentrations of total cholesterol (N: 0.17±22; NC: -16.06±26; p=0.05), LDL 
cholesterol (N: 2.2±15; NC:-10.67±23; p=0.049), and triglycerides (N: 14.6±43; NC: -43.7±45; 
p=0.03). The mean change of HDL did not differ between treatments (N: 0.05±4; NC: 0.33±6; 
p=0.81).   
Conclusions: NC reduced the oxLDL/NOx ratio, a new biomarker of ED, and showed promise in 
improving atherogenic lipids (oxLDL), and non-HDL lipid parameters in human subjects at risk 
for cardiovascular disease. These findings may have implications to reduce the incidence of 
cardiovascular events in diseases with ED.  
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 Introduction  
 Hypercholesterolemia represents a major risk factor for the development of atherosclerosis 
(AS) [4, 60, 251]. Elevated low-density lipoprotein (LDL) concentrations are associated with both 
impairment of endothelial dependent vasodilation and stimulation of atherogenesis [37, 69, 70, 72, 
74]. Vascular oxidative stress is also strongly associated with elevated LDL cholesterol in aging 
[46, 60]. Increased LDL particles are susceptible to oxidative modification when exposed to extra 
release of reactive oxygen species (ROS), particularly, superoxide radicals [27] that contribute to 
scavenging of nitric oxide (NO) and subsequent decrease in biological activity. In general, this 
imbalance between reduced NO bioavailability and overproduction of oxidative stress shifts the 
balance toward increasing ROS to further promote endothelial dysfunction (ED) [151]. During this 
process, oxidized low-density lipoproteins (oxLDL) are made in the vessel wall through oxidative 
modification. Mature oxLDL in the early stages of AS are known to precede the formation of foam 
cells, induce greater impairment in the endothelium than does non-oxidized LDL and consequently 
stimulates the progression of AS [32] when taken up by macrophages [87]. As oxLDL is a key 
determinant involved in all stages of AS [27], reducing the oxidative modification of LDL could 
slow the progression of future cardiovascular events [252].   
 Oxidized LDL and NO are the two characteristic features of ED, and share significant 
antagonistic roles in overall vascular health [60]. While oxLDL is a pro-atherogenic biomarker for 
cardiovascular risk factors, NO is a master signaling anti-atherogenic molecule that maintains 
vascular homeostasis and modulates in vitro lipid peroxidation reactions [52]. NO, presents in 
circulation from two potential sources but direct in vivo measurement of NO cannot be measured 
due to its short half-life (milliseconds) [22, 129, 253]. NO gets rapidly oxidized to nitrate and nitrite 
when it synthesized from the endogenous sources (arginine) by endothelium nitric oxide synthase 
(eNOS) enzyme. Dietary sources (dietary nitrate) is an alternative source of NO generation when 
eNOS is compromised [249]. Thus, nitrite and nitrate acts as stable end products that reflected total 
systemic NO levels from both pathways [129]. Combined measurements of NO metabolic pathway 
products (nitrate+nitrite) termed as NOx [46]. However, these plasma NO metabolites may not be 
good direct biomarkers of long-term nitrate exposure when measured on their own [23]. Likewise, 
plasma oxLDL as an individual parameter is not a strong independent predictor of coronary heart 
disease (CHD) after controlling for other lipid markers [60]. Borsa et al. (2012) [46] reported that 
systemic NO levels were negatively correlated with circulating oxLDL levels in hyperlipidemic 
elderly patients. They also found that the ratio of oxLDL/NOx is strongly correlated with important 
lipid biomarkers: (oxLDL/HDL ), and (TC/HDL) [46], and has been considered as relevant 
biomarker of ED and aging [60]. 
 
 
62 
 There is a growing interest in examining the utility of dietary antioxidants and dietary 
nitrate on the management and reversal of ED and attenuating oxidative stress biomarkers [24, 125, 
182]. Dietary supplementation with inorganic nitrate has been studied as a potential non-
pharmacological therapeutic intervention to restore the biological activity of vascular NO in 
hypercholesterolemia, and increased NO status has been positively associated with improvements 
in endothelial function [74]. Preclinical studies have shown that inorganic nitrate supplementation 
has the potential to reduce well-established markers of vascular oxidative stress [150, 151], but the 
mechanism is unknown. However, scarce data are available demonstrate reduced oxidative stress 
markers in human studies following dietary nitrate supplementation [74, 153-155]. To date, 
Velmurugan et al. [74] found a trend for a greater reduction of oxLDL levels after administering 
250 ml of beetroot juice (~6 mmol) at 6 weeks in patients with untreated hypercholesterolemia 
[74]. A better understanding of the use of dietary nitrate in relation to circulatory oxLDL in 
hypercholesterolemia is needed to further elucidate the dietary nitrate benefit on oxidative stress 
associated ED. 
 Vitamin C (ascorbic acid) is another dietary therapeutic intervention that may augment the 
NO pool and further improve endothelial health through different mechanisms [25]. By scavenging 
oxygen-derived free radicals and thereby preventing interaction with NO, and the subsequent 
formation of toxic oxLDL mediator peroxynitrite, vitamin C supplementation may protect LDL 
against oxidative changes [182, 207]. Another plausible mechanism is that vitamin C plays a role 
in enhancing the exogenous pathway of NO production through dietary nitrate reduction [154]. 
Under hypoxic and acidic condition in blood and gastric lumen, the presence of vitamin C may 
augment the reduction of nitrite to NO. The interaction between nitrate and vitamin C has been 
recently described in the literature and has indicated that vitamin C acts as an enhancer to catalyze 
the non-enzymatic nitrite reduction to NO, thus, increasing the NO pool [147, 218, 236-238].  
NO2 – + H+ → HNO2  
2 HNO2 + vitamin C  → 2 • NO + dehydroascorbic acid + 2 H2O 
 Although dietary nitrate and vitamin C have been independently linked to augmentation of 
NO and reducing oxidative stress, there is a paucity of data that have examined the combination 
effect on cardiovascular health among patients with risk factors for cardiovascular disease. 
Recently, Ashor et al. (2019) demonstrated a significant synergistic effect following single dose 
co-administration of vitamin C with dietary nitrate supplementation on the reduction of 3-
nitrotyrosine (3NT) levels compared to nitrate and vitamin C given alone in healthy individuals. 
These data shed light on the importance of further investigating the additive effect of these two 
dietary components on biomarkers of ED and oxidative stress among subjects with overload 
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oxidative stress. We aimed to target NO-substrate for oxidation with inorganic nitrate and vitamin 
C as a NO dietary supplement strategy in individuals with risk factors of CVD to better improve 
endothelial function by modulating the circulatory detectable markers of ED and oxidative stress 
[46, 88].  
Thus, the purpose of this study was to investigate the combined effects of dietary nitrate 
supplementation with vitamin C for 4-weeks on a biomarker of endothelial function and oxidative 
stress as measured by oxLDL/NOx ratio compared to inorganic nitrate given alone in older adults 
with hypercholesterolemia. We hypothesized that the addition of vitamin C to nitrate 
supplementation would reduce the ratio of oxLDL to NOx status better than nitrate supplementation 
alone. Our secondary outcome was to identify changes in lipid profile between the interventions. 
We expected that the provision of nitrate and vitamin C together for 4 weeks would be associated 
favorable changes to the lipid profile [159, 254]. 
  Materials and methods 
  Subjects 
Male and female non-smokers with a body mass index (BMI) range of (18.5-34.9 kg/m2) between 
the ages of 50 and 70 years of age with high LDL concentrations (>130 mg/dL) were enrolled in 
the study. Subjects were not eligible if receiving lipid lowering therapy, multivitamin supplements 
exceeding >100% of recommended dietary allowance (RDA), or on medications at the time of 
screening that would interfere with the study outcomes (e.g. hormone replacement therapy, 
clonidine, proton pump inhibitors (PPI) and antibiotics). Additional exclusion criteria included 
history of cardiovascular disease, diabetes mellitus, chronic inflammatory disease, celiac disease, 
uncontrolled hypertension (systolic blood pressure >160 mm Hg or diastolic blood pressure >100 
mm Hg), controlled hypertension on clonidine medication, hepatic or renal disease, and active 
cancer. Moreover, subjects who consumed greater than 6 servings of alcohol per week, performed 
structured resistance or aerobic training for more than 1-hour four times per week, or participated 
in other clinical interventions within the previous 30 days were excluded from the study.  
  The study was approved by the university Institutional Review Board, and the informed 
written consent was obtained from all subjects prior to engaging in baseline measures. All 
institutional and governmental regulations concerning the use of human volunteers were followed 
during this research. All study visits were conducted in the Center for Clinical and Translational 
Sciences (CCTS), University of Kentucky, from February 2019 to September 2019.  
  Study design and randomization 
 This was a 10-week cross-over, double-blinded, placebo-controlled study. Subjects 
selected at random to compare the magnitude of change in the oxLDL/NOx ratio (primary outcome) 
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and a lipid profile (secondary outcome) following the 4-week treatment of the dietary nitrate 
supplementation alone (N) and combined with vitamin C (NC) interventions. 
 Eligible subjects were randomized to receive either treatment (N) or treatment (NC) for 4 
weeks (period1), and subjects were then crossed over to the alternate treatment for another 4weeks 
(period 2). There was a 2-week washout at crossover. Throughout the intervention periods, enrolled 
subjects were advised to consume low- vitamin C diet throughout the study. They were provided 
with a list of high vitamin C foods/fortified foods at the first visit to avoid during the study (Figure 
4-1). 
  General clinical procedures 
 After showing interest in the study, potential volunteers were scheduled for a phone 
screening or face-to face interview to assess height/weight for BMI and check inclusion and 
exclusion criteria with brief questions about medical history to check for potential eligibility. 
Anthropometrics measurements and blood draws were performed 4 times throughout the study at 
baseline and endpoint visits of each intervention period. Venous blood samples were collected after 
an overnight fast during the study visit by trained staff at University of Kentucky’s CCTS to 
measure plasma nitrate and nitrite, plasma vitamin C, plasma oxLDL, and a lipid profile. Plasma 
samples were stored at −80°C for analysis at end study. Plasma levels of NO metabolites and 
oxidized LDL were measured pre and post intervention of each treatment to calculate the ratio of 
atherogenic marker (oxLDL) to the biomarker of ED (NO related species ratio (NOx)). We assessed 
this ratio oxLDL/NOx as it could be a more reliable marker than individual parameters. Other 
biomarkers for secondary outcomes were obtained on the same testing days as anthropometric 
measures and included a lipid profile (serum total cholesterol (TC), triglycerides (TG), low-density 
lipoprotein (LDL), and high-density lipoprotein (HDL). All blood draws were measured at baseline 
and endpoint visits of each intervention periods except for the plasma vitamin C concentrations at 
the second baseline visit (baseline2) following the washout period. A washout period of two weeks 
was chosen based on previous work that documented this period was successfully returned NO 
metabolites and vitamin C to baseline level [219, 221].  
Subjects were instructed to maintain their usual dietary patterns throughout the study and 
dietary intake was assessed via 24-hr dietary recall. Three 24-h dietary recalls were collected and 
analyzed using Nutrition Data System for Research (NDS-R, Version 2019, University of 
Minnesota, Minneapolis, MN, USA) at midpoint of each interventional period, covering 1 weekend 
and 2 weekdays for a total of 6 recalls. 
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Figure 4-1. Schematic representation of the study design. 
NO3: inorganic nitrate provided in CBJ dietary supplement. (N): inorganic nitrate and vitamin C 
placebo; (NC): inorganic nitrate and active vitamin C. 
 Plasma biomarkers 
a.  Oxidized LDL and NO metabolites 
Plasma oxidized LDL and nitrate/nitrite were measured by the UK CCTS bioanalytic core lab using 
commercially available assay kits according to the manufacturer’s instructions. A commercially 
available sandwich chemiluminescent immunoassay was used to measure plasma oxidized LDL 
(Mercodia kit, Uppsala, Sweden) based on the monoclonal antibody 4E6 [255]. Nitrate/nitrite are 
measured by the Griess Reaction [239], a reaction that produces a diazonium ion which 
subsequently couples to amine 1-naphthylamine to produce a red-violet color (absorbance @ 540-
570 nM). The assays were done according to manufacture instructions. 
b.  Vitamin c and lipid profile 
Plasma vitamin C and plasma lipid profiles were measured by the UK Hospital Clinical Lab. 
Plasma concentrations of ascorbic acid were analyzed by HPLC. For this measurement, 4.5 mL of 
5% metaphosphoric acid was added to 0.5 mL of plasma within 1 hour after venipuncture and 
stored at -80°C [200]. 
Fasting plasma TG and TC concentrations were determined enzymatically using the 
Specific Clinical Chemistry Analyzer. Heparin– manganese chloride precipitation of plasma was 
used to measure high-density lipoprotein (HDL) cholesterol. LDL concentration was calculated by 
the Friedewald formula [256].  
  Dietary supplementation intervention 
The nitrate supplement was provided to all subjects in the form of commercial beetroot juice 
beverage (Sport Beet IT shot, Heartbeet Ltd). Sport Beet IT was a concentrated beetroot juice (CBJ) 
(70ml) that delivered an average of 300-400mg of inorganic nitrate. Vitamin C and the placebo 
were provided as supplement capsules. The study coordinator was blinded to the treatment 
assignment and the randomization was conducted by investigational Drug service (IDS) at 
University of Kentucky, which prepared the list of randomization treatment sequence and then 
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provided to the study coordinator with the treatment allocation. The preparation and labeling of the 
vitamin C and its placebo were performed in such a way that both pills were identical in shape, 
color, and size to ensure adequate blinding of both subjects and investigators. Vitamin C 
supplements were either active capsules that contained 500 mg of ascorbic acid (Nature Made ®) 
or corn starch in the placebo capsules. The dose of vitamin C provided in this study was based on 
previous work by Ashor et. al who reported in meta-analysis study that 700 mg of vitamin C or 
higher elicited an improvement in endothelial function [25]. The study coordinator instructed 
subjects to self-administer CBJ for 7 days a week at the same time by mouth daily during the 
morning hours and then consume 2 pills (1000 mg of vitamin C or placebo) one hour later.  
 Supplement adherence was assessed by counting the unused pills and beet juice bottles. 
Subjects were asked to return any unused CBJ bottles and vitamin C pills at the following endpoint 
visits of each intervention for pill counts.  
  Statistical analysis 
Using the nQuery Advisor program, sample size calculations were based on the work of Kwak et 
al. (2012) who assessed endothelial function in newly diagnosed type II diabetes subjects [116]. 
Based on these data, nineteen subjects were needed for 80% power with a two-sided p-value of ≤ 
0.05 set for statistical significance. Statistical analysis was performed using Statistical Package for 
Social Sciences (SPSS) software (version 22, IBM, Armonk, NY). Distribution of continuous 
variables were examined by Shapiro-Wilk test. Within treatment group, comparisons at baseline 
and 4-weeks for each treatment were conducted by Paired Student t-tests (for normally distributed 
data) and Wilcoxon signed rank-test test (for non-normally distributed data) for two period data 
separately. Changes in measures over the 4-week period were assessed by calculating the difference 
between the pre and post-intervention measures. Between treatment group, the treatment effect was 
evaluated by the two-sided one-sample t-test which is based on the mean of the differences between 
the two changes for each pair () [240]. Additionally, based on work by Wellek et al. [241] ,we 
examined whether there were any carryover effects from one treatment period to another. Linear 
mixed model was used for secondary analysis to assess the potential interaction effect of variables 
such as BMI and BP medication, sex, and age with the dependent variables in the two treatments. 
Pearson and Spearman correlations were used to assess the relationship between the dependent 
variables. Spearman correlations were used for variables that were not normally distributed. All 
tables reflect data in means ± standard deviation. All graphs reflect data in means ± standard error 
of the mean (SEM). 
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  Results 
 Subjects 
A total of 162 subjects were screened for eligibility and 23 eligible subjects were 
randomized. Of these, 18 completed both interventions and all study visits (Figure 4-2). Subjects 
had a mean age of 594 years and a BMI of 28.33 kg/m2. Thirteen subjects had a BMI ranging 
from normal to overweight ranging from 22.5 to 29.9 kg/m2. Five subjects were obese (class I) with 
a BMI range (30.8 to 34.4 kg/m2). There were no significant differences in baseline characteristics 
between the two treatment sequence groups (sequence 1: N-NC and sequence 2: NC-N) (Table 4-
1). No significant changes in body mass were observed between the two treatment periods.  
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Figure 4-2. Consort Diagram 
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Table 4-1. Baseline Characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BMI: body mass index; BP: blood pressure; NOx: nitric oxide metabolic pathway products (nitrate 
(NO3) + nitrite (NO2)); TC: total cholesterol; LDL: low-density lipoprotein; HDL: high-density 
lipoprotein; TG: Triglycerides. (sequence 1; N-NC): subjects were assigned to randomly start with 
inorganic supplementation alone in period 1 and then crossed over to inorganic nitrate with vitamin 
C in period 2. (sequence2; NC-N): start with inorganic supplementation with vitamin C in period 
1 and then crossed over to inorganic nitrate supplementation alone in period 2. Quantitative 
variables were described as the meanSD. Variables were not significantly different between 
treatment groups at baseline. 
  Ratio of oxidized LDL to nitric oxide metabolites  
 For our primary outcome of examining differences in the ratio of oxLDL/NOx, there was 
a significant reduction following NC compared to N (N treatment: -3.97±2.83 U/L; NC treatment: 
-4.29±3.07U/L; p=0.02). No evidence of a carryover effect was observed from one treatment course 
Variables Treatment N 
(sequence1; N-
NC) 
Treatment NC 
(sequence2; NC-N) 
Total 
 (n=9) (n=9) (n=18) 
Male sex, n (%) 3(33%) 4(44%) 7(39%) 
Age (years) 58±3 59±5 59±4 
BMI (kg/m2) 29.6±3.1 27.1±3.0 28.3±3.2 
Systolic BP (mmHg) 130±15.3 125±11.9 127.5±13.5 
Diastolic BP (mmHg) 84±10.0 81±6.1 85.5±8.2 
Subjects on BP 
medications, n (%) 
3 (33.3%) 3 (33.3%) 6(33.3%) 
Plasma vitamin C 
(mg/dL) 
0.66±0.5 0.88±0.5 0.8 ±0.4 
Plasma NOx (μmol/L) 14.4±5.3 18.9±8.4 16.7 ±7.2 
Plasma oxLDL (U/L) 71.7±8.7 80±14.5 75.9±12.4 
Plasma TC (mg/dL) 235.4±19.9 249.1±48.4 242.3 ±36.6 
Plasma LDL (mg/dL) 135.3±18.4 167.9±41.0 160.6 ±31.7 
Plasma HDL (mg/dL) 55.1±6.5 54 ±11.9 54.56±9.3 
Plasma TG (mg/dL) 119.2±49.1 136±53.4 127.6±50.5 
 
 
70 
to the other (p=0.74). When ratio elements were analyzed separately, no significant difference was 
observed in the change of plasma oxLDL by treatment (N: -1.08.±9.8 U/L; NC: -6.07±9.1 U/L; p= 
0.19) but a significant difference was observed in the change of plasma NOx status between the 
two treatments (N: 94.24±82.9 μmol/L; NC: 128.7±123.5 μmol/L; p=0.01). Secondary analysis did 
not reveal significant interactions between any of the dependent variables and subject 
characteristics such as age, sex, BMI, and BP medications.  
 Within treatment group comparisons revealed that the endpoint oxLDL/NOx ratio was 
significantly lower compared to baseline (p<0.001) (Figure 4- 3A). When oxLDL and NOx 
variables were analyzed separately, NC endpoint oxLDL was significantly lower than baseline 
(p=0.01) (Figure 4- 3B). However, N endpoint oxLDL showed no change over time compared to 
baseline (p=0.64). N and NC endpoint measures of plasma NOx levels were significantly higher 
by time (p<0.001) (Figure 4- 3C). Our secondary analysis indicated that post-supplementation 
changes in plasma NOx level correlated significantly with changes in plasma vitamin C following 
NC treatment (r=0.49, p=0.04) with no correlation seen following N treatment (r=0.29, p=0.26).  
 Vitamin C concentrations 
One subject who started with N treatment was excluded from statistical analysis due to 
missing data at endpoint. There was a significant difference in plasma vitamin C change between 
treatments (N: -0.14±0.53 mg/dL; NC: 0.45±0.66; p<0.001). Within treatment group comparison 
showed that plasma vitamin C concentrations at endpoint increased significantly over time 
following 4-week administration of NC (p=0.01) (Figure 4- 3D).  
 Lipid profile 
 Fasting lipid profile analysis indicated that the mean change in lipids was significantly 
different following NC and N treatments for LDL (N: 2.2±15; NC: -10.67±23; p=0.049) and TC 
(N: 0.17±22; NC: -16.06±26; p=0.05). Serum HDL was unaltered between treatment groups (N: 
0.05±4; NC: 0.33±6; p=0.81). No carry over was evident in LDL (p=0.78), TC (p=0.73), and HDL 
(p=0.93). However, there was a significant carryover effect in TG (p=0.03). Therefore, we 
compared only data of period 1 for TG variable between the two treatments. We demonstrated a 
significant difference in the mean change of TG between treatments (N: 14.6±43; NC: -43.7±45; 
p=0.01). 
 Within treatment group comparison showed no change in TC (p=0.97), LDL (p=0.52), TG 
(0.33), and HDL (p=0.95) from pre- to post following N treatment. In contrast, there were 
significant decreases in TC (0.02) and TG (0.02) with a trend towards a reduction in LDL 
concentrations from pre- to post following NC (p=0.06) (Figure 4-4A-C). HDL did not change by 
time after NC treatment (p=0.83) (Figure 4-4D). Secondary, exploratory correlational analysis 
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demonstrated changes in plasma oxLDL levels correlated significantly with changes in plasma 
LDL (r=0.84, p<0.001) and TC (r=0.85, p<0.001) following NC and N, (r=0.59, p<0.001) and TC 
(r=0.64, p<0.01) respectively.  
 Supplement adherence 
 Overall, subject reported adherence for taking dietary supplements in both interventional 
periods was 99.7% in period1 and 99% in period2 for CBJ, and 98% for period1 and 97.5% in 
period2 for vitamin C. 
  Dietary patterns  
Analyses of three 24-hour dietary indicated that no significant differences in nutrient intake 
and dietary pattern (Table 4-2). Three subjects were removed from the analysis because dietary 
recalls were missed in period 2. 
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Table 4-2. Nutrient Intake and Dietary Patterns  
 N Treatment  
(n=15) 
NC Treatment 
(n=15) 
P-value 
Energy (Kcal) 1757.2±505.2 1571.8±537.7 0.17 
Protein (g) 65.6 ± 16.2 62.8±15.1 0.49 
Carbohydrate (g) 202.9 ± 81.0 177.6±88.7 0.26 
Fat (g) 80.9 ± 31.9 69.9±23.9 0.12 
MUFA (g) 27.5 ± 11.6 26.1±9.7 0.58 
PUFA (g) 17.7 ± 10.2 13.8±5.2 0.13 
SFA (g) 29.2±14.0 24.0±10.7 0.057 
Vitamin C (mg) 46.5±23.9 59.6±49.4 0.23 
Vitamin E (mg) 10.3±5.4 9.8±3.5 0.69 
Alcohol (g) 3.4±6.1 2.6±4.4 0.24 
Caffeine (mg) 244.1±132.2 243.6±120.9 0.98 
Dietary patterns    
Dark-Green 
vegetables 
Servings/day 
0.56±0.7 0.59±0.7 0.92 
Cured meat 
Servings/day 
0.05±0.1 0.07±0.1 0.22 
 
MUFA: mono-unsaturated fatty acids; PUFA: Poly-unsaturated fatty acids; SFA: Saturated fatty 
acids. P value were calculated from paired t-test between N vs. NC. N Treatment: inorganic nitrate-
rich beet juice and vitamin C placebo or NC Treatment: inorganic nitrate-rich beet juice and active 
vitamin C (1000mg). Values were not significantly different between treatment groups. Values are 
presented as mean ±SD.  
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A         Treatment group = 0.32†                 Treatment group = 34.5†      
 
Treatment group = -4.99          Treatment group  = 0.58† 
 
                                                     
Figure 4-3. Circulatory biomarkers in response to 4 weeks interventions.  
OxLDL /NOx: Oxidized low-density lipoprotein to nitric oxide metabolites ratio (n=18) (3A), 
NOx: plasma NO metabolites (n=18) (3B), oxLDL: plasma oxidized low-density lipoprotein 
(n=18)( 3C), and plasma vitamin C (n=17) (3D) before (dark gray panel) and after 4-weeks of 
supplementation (white panel) with (N): inorganic nitrate and vitamin C placebo or (NC): inorganic 
nitrate and active vitamin C. Values represent means ± SEM. Data were analyzed using paired t-
test for oxLDL and vitamin C, and Wilcoxon-test for  the ratio and plasma NOx, *p ≤0.05. = mean 
difference between the two changes for each pair. Data were analyzed using one sample t-test, 
†P<0.05. 
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A            Treatment group = -16.2†  B Treatment group=12.9† 
  
C            Treatment group =  0.38   D  Treatment group = -58.3† 
 
 
 
 
Figure 4-4. Serum Lipid profile in response to 4 weeks interventions.  
TC: Total cholesterol (n=18) (4A), LDL: low-density lipoprotein (n=18) (4B), HDL: high-density 
lipoprotein (n=18) (4C), and TG: triglycerides (n=9) (4D) before (dark gray panel) and after 4-
weeks of supplementation (white panel) with (N): inorganic nitrate and vitamin C placebo or (NC): 
inorganic nitrate and active vitamin C. Values represent means ± SEM. Data were analyzed using 
paired t-test for all lipid profile parameters, *p ≤0.05. = mean difference between the two changes 
for each pair. Data were analyzed using one sample t-test, †P<0.05.   
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  Discussion 
  Endothelial dysfunction and oxidative stress biomarkers 
This study was the first examination of a potentially therapeutic dietary supplement 
approach investigating the impact of NC versus N supplementation on the magnitude of change in 
the oxLDL to NOx ratio and associated cardiovascular biomarkers. The ratio of oxLDL/NOx is a 
new marker of endothelial dysfunction associated with aging [46, 60]. The most significant finding 
from this work was the reduction in the ratio of oxLDL to NOx status following NC treatment. This 
finding supports our hypothesis that the addition of vitamin C to nitrate supplementation yielded a 
greater reduction in the ratio of oxLDL/NOx status compared to nitrate supplementation alone. 
The significant treatment group effect on our oxLDL/NOx ratio outcome appears to be 
largely driven by NOx changes. We observed that the greatest reduction in oxLDL/NOx ratio over 
4 weeks was associated with NOx levels between treatment groups. NOx levels were ~2 fold higher 
in NC than in N treatment. Our finding suggests that the addition of vitamin C supplementation to 
inorganic nitrate supplementation produced greater improvements in plasma NOx bioavailability 
resulting in greater reduction in oxLDL/NOx ratio. The elevation of total plasma NOx and vitamin 
C concentrations following NC confirm the capacity of vitamin C as a potent reducing agent to 
nitrite reduction [24-28], which in turn appears to increase the circulatory NO pool greater than 
nitrate supplementation alone.  
 Based on promising findings from both animal [150, 151, 257, 258] and human studies 
[153, 154] that reported a reduction in well-established blood markers of oxidative stress, we 
expected to see treatment group differences in oxLDL change following N versus NC treatment. 
However, no treatment group differences were observed. When evaluating the effects of individual 
treatments over time, N  showed no changes in oxLDL levels which are in line with a previous 
report by Velmerurgan et al. (2015) [74], showing that the administration of a similar dosage of 
dietary nitrate supplementation (~6mmol) for 6 weeks had no effect in untreated 
hypercholesterolemic adults. Similarly, Larsen et al. [155] reported no changes in total antioxidant 
capacity and plasma isoprostanes F2 following 3 days administration of inorganic nitrate 
supplementation. One factor that could contribute to the disparity between studies examining 
dietary nitrate and oxidative stress could be that studies evaluate oxidative stress with different 
blood markers [153]. The second factor could be differences in the magnitude of oxidative stress 
between subjects in various studies that may require higher antioxidant dose to reduce LDL 
oxidation [153]. The strong association we observed between circulating oxLDL and plasma lipid 
profile (TC and LDL) in both treatments underscore the value of oxLDL as a biomarker for  
atherosclerosis in subjects with hypercholesterolemia. Based on our findings and work from others 
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[74] who studied a similar oxidative stress marker, 6mmol of dietary nitrate for a 4-week study 
duration may not be sufficient to modulate oxLDL. In contrast, inorganic nitrate favorably modified 
oxLDL levels when examining within-group changes over time following NC treatment. After only 
four weeks, the oxLDL reductions suggests that the addition of vitamin C to inorganic nitrate 
produced a clinically significant change in oxLDL by -6.07 U/L in hypercholesterolemic adults. 
These findings are in accordance with a recent study that found a synergistic effect of acute single 
dose of combined nitrate and vitamin C supplementation on the oxidative stress marker of  3-NT 
[154]. We speculate that the combined antioxidant capacity of inorganic nitrate and vitamin C 
complement each other to augment NO production as well as a decrease of oxidative stress in 
subjects at risk of CVD. Furthermore, to our knowledge, many previous studies have demonstrated 
benefits of vitamin C supplementation in the absence of inorganic nitrate have shown that vitamin 
C reduces the susceptibility of LDL to oxidation in vitro [198, 199]. However, the effect of vitamin 
C supplementation on circulating oxLDL levels have been rarely examined. Two previous studies 
have examined same dose of 500 mg for 4-weeks  [200] and 12weeks [259] in subjects with CVRFs. 
The former found no association with changes in circulating oxLDL, while the latter found a 
chronic supplementation of vitamin C associated with lowering oxLDL by -18.32 U/L. Although 
the current study did not look at the changes following vitamin C alone, we found a short-term 
intervention of NC treatments for 4 weeks reduced circulating oxLDL by 6.07U/L. Therefore, it is 
worthwhile to design a study that compared the NC effect versus vitamin C alone on oxidative 
stress marker and lipids.  
 The potential therapeutic benefits of NC for the reduction of oxLDL to NOx ratio can be 
attributed to two proposed mechanisms: the abundance of NO availability surrounding oxidants 
may have a direct effect on attenuating the lipid peroxidation reaction into the vascular wall [46]. 
Some studies have suggested that NO derived from exogenous nitrate supplementation possesses 
antioxidant properties that may reduce vascular oxidative stress in vivo in humans [153]. However, 
this is less clear and still requires further investigation to examine the antioxidant therapeutic 
potential effect of dietary nitrate alone in humans in vivo oxidative stress. The second mechanism 
could be explained by the indirect effect of a strong antioxidant vitamin C on augmenting NO 
bioavailability through inhibiting the ROS. This inhibition might shift the balance back toward NO 
while in turn protecting its bioavailability from ROS interaction and oxLDL formation [182, 207]. 
Overall, the sustained efforts must be undertaken to translate these results to be clinically significant 
before applying this ratio in clinical practice. Although the statistical significance between the two 
treatments highlighted that this ratio was influenced with short-term dietary supplementation, it 
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would be worthwhile to investigate whether a long- term dietary supplementation intervention 
could make a clinically significant difference.  
 Lipid profile  
 This was the first study that examined the combined effect of NC on lipid profiles in older 
adults with CVRFs. NC produced a significant reduction in many lipids compared to N. We found 
that NC treatment provided substantial reductions in TC (-16.1 mg/dL), LDL (-10.7 mg/dL), and 
TG (-43 mg/dL) but failed to produce a significant increase on HDL cholesterol. This translated to 
approximately a 6.6 % reduction in TC and LDL and a 32% reduction in TG in 4 weeks. These 
results support the second half of our hypothesis suggesting that the addition of vitamin C to 
inorganic nitrate supplementation produced favorable changes in lipid profiles. Our findings are of 
particular interest because the magnitude of change on different blood lipids are greater when 
compared with the magnitude of change seen in a recent meta-analysis [202]. This meta-analysis 
investigated the effect of vitamin C supplementation (500 mg) for 4 to 24 weeks on blood lipids 
concentrations only in hypercholesterolemic adults with a pooled mean age of 58.9 years. Thirteen 
trials which included subjects with hypercholesterolemia found that TC, LDL, and TG decreased 
by -10.76 mg/dL, -7.9mg/dL, and -20.1 mg/dL. This translated to approximately a 4.5% reduction 
in TC, a 5% reduction in LDL and an 8.8% reduction in TG. 
  Some preclinical studies have shown that inorganic nitrate and nitrite administrations have 
the potential to reduce TG concentrations [156-158]. To our knowledge there are limited clinical 
trials that have investigated these outcomes, including a few studies with equivocal findings [39, 
74, 159, 163]. Three trials did not show an effect of dietary nitrate on lipid biomarkers [39, 74, 163] 
and these studies support our findings following 4 weeks of N treatment. However, two trials 
reported that inorganic nitrate supplementation had favorable effects on dyslipidemia [159, 254]. 
One study found that 250 ml of raw beetroot juice for 14 days in hypertensive subjects reduced 
plasma TC by ~15 mg/dL and LDL by ~14mg/dL compared to baseline [254]. Another study 
examined the 30-day effect of tablet containing nitrate derived from beetroot along with the 
antioxidant hawthorn berry [159]. The authors found a significant increase in plasma nitrate and 
nitrites, and a 27% reduction in TG concentrations compared to pre-treatment concentrations in 
hypertriglyceridemia subjects. When comparing our results with the Zand et al. [159], it is 
important to note that the percentage of the TG lowering effect (-32%) seen in our work after only 
4 weeks of NC was similar to the percentage of TG reduction shown with neo40 [159]. We have 
also noted from our findings that NC improved not only TG but all non-HDL parameters (TC, LDL, 
and TG). Collectively, the improvements in blood lipids from Zand et al. [159] and our work 
suggests that dietary nitrate supplementation in the form of beet juice may be a valuable dietary 
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supplement to combat dyslipidemia. However, the addition of the antioxidant vitamin C may serve 
as a significant enhancer for augmenting the dietary nitrate effect to promote improvement in 
plasma nitrate levels and induce reduction in non-HDL parameters which could positively impact 
overall cardiovascular health. In regards to mechanism of action, studies have revealed that nitrate 
and nitrite may affect fat metabolism and energy utilization [156, 260]. Roberts et al. demonstrated 
that nitrate induced mitochondrial “browning” and increased fat oxidation in white adipocytes 
[260]. However, the exact mechanism explaining the nitrate effect on blood lipids remains to be 
determined. Combined with vitamin C, it is unknown if systemic NO accumulation has a direct 
effect on blood lipids or if the direct beneficial effect is explained by vitamin C supplementation. 
In addition, it has been suggested that vitamin C supplementation may enhance the reduction of 
serum lipids through two mechanisms either by enhancing the conversion of cholesterol to bile 
acids or by counteracting the oxidation of LDL. As a result of both mechanisms, vitamin C 
increases the uptake of LDL by the liver cells, hence, promoting LDL removal from the plasma 
concentrations [202, 205, 206, 261].  Future studies with four arms will determine if the reduction 
of oxidative stress and lipid parameters was a result of the co-administration of inorganic nitrate 
with vitamin C or was a response to vitamin C intervention alone. Further animal studies are 
required to elucidate the mechanism behind the observed effects.  
  Strengths and limitations 
This was the first study targeting the ratio of oxLDL/NOx with therapeutic interventions to 
evaluate the status of endothelial function in an older adult population with CVRFs. The strengths 
of this study include the study design that controlled variability between subjects, and high 
supplement adherence. There were also some limitations to consider when interpreting these 
results. The major limitation in this study was the small sample size. The study was powered for 
the primary outcome measure of the absolute change in the RHI response at 4 weeks from 
baseline. Although we were able to demonstrate differences between placebo and active vitamin 
C interventions in most variables, comparison interpretations between N and NC should be made 
cautiously. It is important to note while the carryover effect may not have reached statistical 
significance in most of the variables, the small sample size may have driven that. Although we 
tested that carry over effect between the two treatment periods and no effect was observed in 
most variables, a number of exploratory analyses in addition to the carryover effect of some 
variables were conducted for which the study was not powered including all of the outcomes of 
study aim 2. Another limitation was the inability to compare NC outcomes with the vitamin C 
supplementation only group. The current study did not look at the changes following vitamin C 
alone, therefore we cannot compare our findings with very limited published studies that 
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examined the link between vitamin C and circulating oxidized LDL. In addition, the small sample 
size with a short study duration of 4 weeks may have not been sufficient to detect the 
responsiveness of oxLDL to dietary nitrate supplementation. Furthermore, the lack of measuring 
additional biomarkers of oxidative stress such as plasma concentration of isoprostane, a stable in 
vivo marker of lipid peroxidation prevents us from further elucidating the benefit use of dietary 
nitrate on oxidative stress.  
 Conclusion 
 In conclusion, the provision of vitamin C combined with dietary nitrate supplementation is 
a natural, cost effective strategy that reduced oxLDL/NOx ratio and blood lipids in our sample of 
older adults with hypercholesterolemia. Our results suggest that targeting endothelial function and 
restoring the reduction of NO with a novel combination of dietary supplements promoted favorable 
changes on markers associated with cardiovascular disease. Dietary nitrate and vitamin C have 
been identified as key components in the dietary pathway to augment NO production. Eating a diet 
rich in high nitrate vegetables combined with vitamin C rich foods, may also provide a greater NO 
reservoir in diseases associated with ED and decreased eNOS activity and require further 
investigation.  
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 GENERAL DISCUSSION 
This dissertation work focused on a novel dietary supplement intervention for the purpose of 
improving endothelial dysfunction (ED) in older adults at risk of cardiovascular disease. We 
compared the effectiveness of two, 4-week supplementation treatments consisting of inorganic 
nitrate in the form of concentrated beetroot juice with and without vitamin C on the magnitude 
changes of endothelial function (EF), oxidative stress, and lipid profile outcomes. We also 
compared the treatment effect on the aforementioned outcomes within each treatment group (before 
and after each treatment).  
The primary outcomes of this dissertation were changes in clinical measures (Chapter 3) 
and blood biomarkers of endothelial function (Chapter 4) as determined by reactive hyperemia 
peripheral arterial tonometry index (RHI) and the ratio of oxidized LDL (oxLDL) to nitric oxide 
metabolites (NOx), respectively. Comparing the two treatments groups, we found no significant 
differences in the change of RHI in the overall sample of older adults with hypercholesterolemia 
and a baseline RHI less than 2. We also found that NC promoted greater augmentation of nitric 
oxide (NO) bioavailability that may have potentiated greater improvements in endothelial function 
in older adult subjects with hypercholesterolemia. In addition, we evaluated whether RHI was 
influenced by subjects’ characteristics (age, blood pressure medications, baseline BMI, baseline 
RHI, and sex), and found that RHI significantly improved in subjects with greater endothelial 
dysfunction at baseline (RHI <1.67) than those who entered the study with mean RHI greater than 
1.67. No other interactions between subject characteristics and our dependent variables were found.  
Although no treatment differences were observed with our clinical measure of endothelial 
function, we found in the second aim of the study (Chapter 4 significant improvements in the 
change of oxLDL/NOx ratio, plasma vitamin C, and circulatory biomarkers of NO metabolites 
(nitrate and nitrite) were observed following nitrate and vitamin C co-supplementation (NC) 
compared to nitrate supplementation alone (N). In addition, vitamin C co-administration with 
inorganic nitrate showed a better response in reducing serum lipid profiles, particularly, total 
cholesterol (TC), low-density lipoprotein cholesterol (LDL), and triglycerides (TG) concentrations 
compared to nitrate alone. No differences were observed between treatment groups in HDL and 
oxLDL concentrations in hypercholesterolemic older adults.  
Regarding to the dose-response -relationship and study duration, we used similar doses of 
NC to the previous work by Ashor et al. [154] and found that the addition of vitamin C for a longer 
duration (4 weeks) modified the effect of nitrate supplementation on the plasma nitrate response 
and produced additive improvements in the NOx accumulation. These results suggest that the 
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treatment effect of nitrate with vitamin C on NO metabolites may have been attributed to both the 
dose of the supplementation and the longer duration of treatment. However, when examining within 
treatment comparison of dietary nitrate alone on oxidative stress and lipid profile, we demonstrate 
that 6 mmol of nitrate in the form of CBJ for a duration of 4 weeks may not be sufficient to 
contribute to a meaningful alteration in the oxidative stress marker of oxLDL, and lipid profile. 
This findings was consistent with previous work by Velmerurgan et al. [74], that showed 6 mmol 
of dietary nitrate in the form of beet juice for a longer duration of 6 weeks was not effective to 
reduce oxLDL when examining within treatment comparison. The results presented in Chapter 4 
demonstrated that introducing a daily 1g dosage of vitamin C with 6 mmol of dietary nitrate was 
associated with significant increases in both plasma ascorbate and plasma nitrate concentrations. 
We noticed that this combination over 4 weeks showed signs of ameliorating oxidative stress. We 
speculated that antioxidant protection provided by vitamin C may be complementing the dietary 
nitrate effect to reduce the oxidative damage and blood lipids in hypercholesterolemic adults greater 
than 50-year-old. Our results suggested that the provision of vitamin C with inorganic nitrate can 
protect against in vivo lipid peroxidation measured as oxLDL. This signifies the potentiation of the 
effects of both supplemental agents when introduced together. 
In regards to the impact of aging on dietary nitrate interventions, we found the 
administration of inorganic NO3 with and without vitamin C to our selected population of older 
adults was associated with a significant increase in the levels of plasma NOx with no effect on 
endothelial function. Aging is a risk factors associated with a number of functional changes in 
multiple organ systems, including the vasculature, that affect the functioning of all body systems 
[262, 263]. Previous evidence has demonstrated that low gastric acid, low vitamin C absorption, 
and changes in oral and intestinal microflora associated with aging [264] may modify the reducing 
steps in the conversion of dietary nitrate to NO, and the efficiency of dietary nitrate to generate a 
beneficial microvascular response [167]. Our findings suggest that a 6mmol dosage of inorganic 
nitrate derived from CBJ produced substantial changes in NO metabolites that led to increasing the 
NO pool in adults greater than 50-year-old in 4 weeks. This augmentation may be clinically 
significant by helping to overcome endothelial nitric oxide synthase (eNOS) dysfunction associated 
with cardiovascular risk factors. It seems that aging has no impact on the ability to increase levels 
of NO metabolites as long as adequate exogenous substrates are provided [124]. Our results support 
recent studies that have demonstrated beneficial effect of inorganic nitrate supplementation on NO 
metabolites in older adults at risk of cardiovascular disease [140, 165].  
Data synthesis of the two aims in my dissertation revealed greater improvements in the NO 
bioavailability after supplementation with large doses of NC for short-term intervention compared 
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to N. These results align with previous studies that both dietary nitrate and vitamin C have potential 
roles to improve NO availability through different mechanisms [24, 207], and both have antioxidant 
properties to reduce oxidative stress and protect NO from being oxidized by reactive oxygen 
species [155, 182]. NO improvement following the daily administration of NC was the reason 
behind the successful improvements of endothelial function, oxidative stress marker, and blood 
lipids which may have positive impact on cardiovascular health.  Moreover, we found out that the 
changes of oxLDL/NOx ratio and non-HDL lipid markers were not associated with the change of 
RHI score suggesting that some of the beneficial effects of inorganic nitrate and vitamin C co-
supplementation were not dependent on changes in clinical measures of endothelial function. 
Findings from this dissertation provided evidence of concept that NO can be increased as a result 
of CBJ supplementation, particularly when combined with vitamin C, in subjects with 
cardiovascular risk factors.  
 Strengths: 
There are several key strengths in this dissertation.  
• The major strengths of this study are the double-blinded placebo controlled cross-over design, the 
low dropout rate, and the high adherence to treatment in both periods and the restricted inclusion 
and exclusion criteria.   
• Another strength was the examination of numerous markers associated with cardiovascular disease.  
• This study demonstrated the potential of beneficial effect of nitrate combined with vitamin C on 
markers associated with cardiovascular outcomes. 
• Subjects adherence to maintaining their usual diet during the two study periods. Our dietary 
analysis showed no difference in dietary intake or dietary pattern between treatment sequences. 
This suggests that diet did not influence our between treatment study outcomes. 
 Limitations:  
Many of the study limitations were related to data collection methodology that need consideration 
when designing future studies. 
• A major limitation in both aims was that the data was underpowered for some variables due to the 
small sample size.   
• Our study protocol did not emphasize the importance of recording the exact timing of vitamin C 
ingestion. This precluded the ability to conduct a secondary analysis aimed at analyzing the 
interaction of timing of vitamin C ingestion with endothelial function outcomes.  
• Another limitation was related to the uses of the peripheral arterial tonometry (PAT) for assessment 
of endothelial function. RHI scores were highly variable and limited statistical power given the 
small sample size. The sensitivity of endoPAT test to NO production and its contributions of other 
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molecules besides NO to assess endothelial function may limited our ability to detect the 
differences between treatments. 
• Additional limitations were due to study budget constraints. We were unable to collect specific 
biomarkers such as expelled air of stomach NO, or circulatory endothelial function markers 
including endothelin1, soluble endothelial marker with adhesion molecules, and asymmetric 
dimethylarginine. The intra-gastric NO marker may provide more insight to the interaction site and 
the amounts of NO formed from the entero-salivary circulation, while the other markers may 
provide a clearer picture on how the NC intervention influence key molecules that contribute 
improvement in endothelial function.  
• Another study limitation was the lack of dietary assessment during the washout phase. The dietary 
assessment during this phase might clarify if the subjects changed their quality of diet that could 
affect their results in baseline visit post washout period.  
• Finally, although all subjects agreed to maintain their physical activity throughout the study 
duration and to restrict their exercise to no more than 1 hour a day for 4 times a week, the role of 
physical activity as a potential confounding variable was not assessed throughout the study. Due to 
physical activity being a factor influencing positively the integrity of endothelial function [227, 
265, 266], changes in activity patterns throughout the study duration could have affected the study 
outcomes, particularly, RHI. 
 Clinical implications  
The NC combination may have implications in improving endothelial function through 
restoring NO availability in populations with impaired endothelial function. This combined 
supplementation strategy may have utility of other patient populations with disease etiologies that 
include endothelial dysfunction and oxidative stress such as aging, young adults with untreated 
hypercholesterolemia, and hypertension. It is unknown whether our intervention will have similar 
effect on different populations with higher risk of cardiovascular complications such as diabetes. 
There is a paucity of studies examined inorganic nitrate effect on vascular health among diabetic 
patients. Targeting those populations may have public health implications contribute to improve 
their vascular health and further their quality of life. 
Based on the Atherosclerotic Risk in Communities Study [267], a reduction of LDL 
concentrations by -7.9 mg/dL equated to a decrease in the coronary heart disease (CHD) risk of 
6.6%. A reduction in TG by -20mg/dL could be translated to a 2.4% reduction in CHD risk [202].  
It is worthwhile to note the percentage of reduction in our findings exceeded these values and have 
significant clinical benefits in reducing the incidence of coronary heart disease, especially when 
combined with a healthy lifestyle. My dissertation research suggests dietary changes that include 
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increasing consumption of dietary nitrate sources such as green leafy vegetables and beet juice with 
vitamin C foods that would be helpful –”food-first” approach which may have implications to lower 
lipid profile and oxidative stress and further slow the progression or the incidence of cardiovascular 
events in diseases with ED.   
 Future directions 
While this project provides preliminary evidence that combination of nitrate and vitamin C elicited 
improvements on markers of endothelial function, oxidative stress, and lipid profile, several 
questions remain to be unanswered.  These questions can be answered questions in the future 
studies.  
• The primary need is for this study to be replicated in a larger sample in a RCT. In addition, 
identifying the mechanism related to how these supplements interact when consumed together to 
result in favorable changes in blood lipids and reduced LDL oxidation needs to be determined in 
future animal studies.  
• It would be interesting to stratify the co-administration of vitamin C with dietary nitrate into two 
groups: together at the same time versus introducing vitamin C an hour after beetroot juice 
supplementation to identify whether the timing of vitamin C ingestion would matter or not on the 
same study outcomes.  
• To gain a better understanding on the impact of nitrate and vitamin C on subjects with poor 
endothelial function, identifying older adults subjects with reduced RHI scores (<1.67) at baseline 
should be considered to detect a treatment effect to examine the effect of dietary nitrate on vascular 
health. Another suggestion to further explore the NC treatment effect would be testing the 
endothelial function in a larger study population since FMD is a gold standard method to determine 
a potential role of this intervention in endothelial function. 
• Most of the published studies examined dietary nitrate on vascular function were used small sample 
size and have excluded all vasoactive medications from the study. Focusing on diet modifications 
as complements to conventional pharmacological therapy may improve cardiovascular health.  
Future research efforts should be given to the design of trials testing co-supplementation of dietary 
nitrate and vitamin C in hypercholesterolemic subjects with and without cholesterol lowering 
medication (statin) to evaluate whether NC intervention provides additive effects beyond 
pharmacological therapies on the same outcomes we used in our study.  
• In addition, it would be interesting to investigate the following in future studies: 1) whether the 
dietary nitrate and vitamin C supplements when consumed together would sustain their efficacy 
and sustainability of the physiological effects in longer chronic interventional trials > 4 weeks; 2) 
whether smaller supplemental doses, that correspond to vitamin C and nitrate intake expected in a 
 
 
85 
plant-based diet, would produce similar effect on endothelial function, lipid profile and oxidative 
stress markers as the doses we used in our study; 3) whether oxLDL reduction may require either 
a longer time course or higher dosage of nitrate supplementation alone since the data describing 
dietary nitrate use on circulating oxLDL is still scarce. 
• It is worthwhile to examine the effect of introducing vitamin C-rich foods an hour after dietary 
nitrate consumption. Vitamin C from food may complement the beneficial effects of dietary nitrate 
on cardiovascular health and may reduce the supplement burden for consumers.  
• Moreover, some recommendations I suggest when designing future studies are the following 1) 
design effective ways to encourage subjects to report the exact time of daily dietary supplement 
ingestion. 2) continue to explore and refine other dietary supplementation strategies with  dietary 
nitrate that target the NO exogenous pathway to work more efficient and overcome the deficiency 
of endothelial NO derived from arginine before the presence of clinical manifestations of 
atherosclerosis  [24, 124]. There are several options for dietary nitrate supplementation instead of 
the CBJ such as tablets or beet bars. These options might be more palatable and feasible than the 
beet juice. However, very little studies have tested their effects. 
 Conclusion  
My dissertation research sheds light on the beneficial use of vitamin C with dietary nitrate 
supplementation as a therapy for improving endothelial function. The results from this valuable 
experience have encouraged me to continue developing research projects in the future to tackle 
cardiovascular disease with innovative dietary supplement approaches.  
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